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ABSTRACT 
Angelman syndrome (AS) is a rare genetic disorder affecting 1/10,000 to 1/20,000 births. This 
disorder arises through the genetic disruption of the maternal UBE3A allele, which when coupled 
with epigenetic silencing of the paternal allele UBE3A allele, gives rise to an absence of UBE3A 
protein in the central nervous system. Clinical manifestations of the syndrome vary in severity and 
include poor motor function, deficits in language and severe intellectual impairments. Previous 
research in the Angelman syndrome mouse model revealed abnormalities in dendritic spine density 
and morphology of hippocampal pyramidal cells. As seen in humans with AS, mice show 
abnormal behavioral characteristics that include deficits in motor coordination and ability as well 
as hippocampal dependent associative fear conditioning. Physiologically, these animals exhibit 
severe deficits in long-term potentiation (LTP) when compared to wildtype littermates.  
In an attempt to reduce the time from laboratory study to human translation, we began to 
search a small molecule library for established compounds with the ability to improve the 
behavioral and physiological defects normally associated with the AS mouse. One compound, 
minocycline, was found to normalize the density of dendritic spines in the hippocampus as well as 
recover the associative memory of AS mice. Moreover, a significant increase in LTP after theta-
burst stimulation was also observed in area CA1 hippocampal pyramidal neurons of AS mice 
treated with minocycline when compared to saline vehicle control mice. These results suggest 
treatment with minocycline improves synaptic function and learning and memory of AS mice and 
may provide similar improvements to patients with Angelman syndrome.  
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Twenty-five participants ages 4-12 were enrolled in a clinical trial examining the safety and 
tolerability of minocycline in children with Angelman syndrome. Patients were evaluated at 3 time 
points, baseline (T1), after 8 weeks of treatment (T2) and again 8 weeks after the drug was 
discontinued (T3). Each evaluation was identical and included laboratory testing, EEG recording 
and neuropsychological examination. Results of the study showed minocycline was safe and well 
tolerated with only minor adverse effects reported. While no change was observed in EEG 
recordings, significant increases in the mean clinical global impressions severity scale score were 
observed after treatment with minocycline. Moreover, participants showed significant 
improvement in the raw scores of the communication and self-care domains of the Bayley Scale 
of Infant and Toddler Development, 3rd Edition. These results show for the first time, a therapeutic 
with the ability to improve the characteristic behaviors of Angelman syndrome.  
Unfortunately, currently available neuropsychological measures were found to be 
insensitive to the behavioral phenotype of AS. The primary outcome measure, the Bayley Scale of 
Infant and Toddler Development, 3rd Edition relies on verbal communication and for the examinee 
to perform specific tasks on command. These testing methods are not compatible with this patient 
population and resulted in raw scores outside of 2 standard deviations from the mean. The inability 
of the participants to perform on these exams led us to develop a novel outcome measure; one that 
relies on observation rather than verbal communication. 9 children with AS and 7 healthy children 
were enrolled in an observational study in which 30 minutes of free play activity was video 
recorded. Using behavioral coding software, 3 independent raters quantified stereotypical AS 
behaviors as well as communication methods. Speech attempts were categorized into five 
difference types of vocalizations and revealed children with AS used less advance forms of 
vocalization consisting mostly of phonation control. Phonetic inventories show mostly front or 
viii 
 
back vowel usage suggesting little tongue movement occurs during speech production. These 
results suggest deficits in verbal ability may be related to a childhood apraxia of speech.  
Impairments in balance and motor coordination have been associated with AS. In an 
attempt to measure gross motor function, spatiotemporal gait parameters were collected using an 
electronic walkway and gait analysis software. Results show the gait of children with AS most 
resembles that of patients with ataxia but without cognitive impairment. In an attempt to develop 
a single quantitative measure able to describe the severity of gait-related disability, statistical 
methods were used to create a gait index for patients with AS. The results of this study provides 
AS researchers with the tools necessary to accurately measure changes in behavior and gait during 
the clinical evaluation of potential therapeutics. 
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CHAPTER 1 
 
INTRODUCTION 
Angelman Syndrome 
In 1965, Dr. Harry Angelman first described three children, of normal birth to healthy 
parents, which exhibited similar symptoms including microcephaly, frequent fits, profound mental 
retardation, lack of speech, ataxia, easily provoked laughter and a protruding tongue (Angelman 
1965). Initially coined as “happy puppet children”, this derogatory description was later renamed 
to Angelman syndrome (AS). Further research revealed other common features of the syndrome 
that include, but are not limited to feeding/suckling problems, delays in motor abilities, 
hyperreflexia, strabismus, widely spaced teeth and seizure with electroencephalogram (EEG) 
abnormalities (Clayton-Smith and Pembrey 1992).  
Clinical Presentation  
Diagnostic Criteria 
Published in 1995, a revised consensus statement was published that summarized the 
clinical features of Angelman syndrome in an attempt to facilitate the diagnosis of patients in 
which Angelman syndrome is suspected (Williams, Beaudet et al. 2006). The developmental 
histories of Angelman patients reveal normal prenatal and birth history and an absence of major 
defects. As neonates and infants, these patients have difficulty feeding and, by 6-12 months of age, 
truncal hypotonicity with jerky movements of the limbs become evident. Patients will exhibit a 
progressive but delayed development. Laboratory values will reveal normal metabolic, 
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hematologic and chemical profiles. Normal brain structure, with or without cortical atrophy or 
dysmyelination, will be observed using MRI or CT scans (Williams, Beaudet et al. 2006).  
Infants with AS will exhibit truncal hypotonia and present as floppy with hypertonicity of 
the limbs. Consistent (100%) clinical features of AS include a severe developmental delay and 
disorders in balance and movement. While typically developing children begin to sit independently 
between the ages of 4 to 7 months, children with AS begin to sit unsupported at approximately 12 
months of age. Moreover, children with AS do not progress to crawling (or cruising) until 18 to 
24 months of age while a typically developing child will begin to pull up and ambulate 
independently at 9 months. Walking will be delayed until an average age of 4 years old and will 
be ataxic and dyspraxic with a wider than normal base of support and tremulous movement of the 
arms and legs. Frequent laughter, smiling and happy demeanor are behaviorally unique to patients 
with this syndrome. This behavior is accentuated by hypermotoric behaviors such as hand flapping 
or waving motions (Clayton-Smith and Pembrey 1992). While there are several other features of 
AS (Table 1-1) that occur less frequently (>80%), the most severe is seizure, which emerges prior 
to 3 years of age and confirmed by abnormal electroencephalogram (EEG) (Williams, Beaudet et 
al. 2006) 
Polygraphic Pattern Profile of Angelman Syndrome 
  Several reports have shown children exhibiting the clinical features of AS also exhibit 
characteristic electroencephalogram (EEG) wave patterns even if the patients have had no history 
of seizure (Boyd, Harden et al. 1988). Clinical research agrees in the existence of 3 main 
characteristic EEG patterns including: 1) Prolonged runs of high amplitude (200-500µV) rhythmic 
2-3Hz (delta) activity over the frontal regions with superimposed interictal epileptiform discharges 
(83.5% prevalence). 2) High amplitude rhythmic 4-6Hz (theta) activity, prominent in the occipital 
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region with spikes facilitated by eye closure. 3) High amplitude (<200µV) spikes and sharp waves 
mixed with 3-4Hz components mainly in the posterior facilitated by eye closure (Laan and Vein 
2005, Vendrame, Loddenkemper et al. 2012). The aforementioned wave patterns are so consistent, 
even amongst the various genotypes, Vedrame et al. suggest these patterns should be used as a 
biomarker in the diagnosis of the syndrome (Vendrame, Loddenkemper et al. 2012). For example, 
in a separate study researchers evaluated 144 patients with severe epilepsy and cognitive 
impairment. Of those patients, 10 met diagnostic criteria of Williams et al. and one, despite the 
absence of clinical features of AS, was identified and diagnosed (confirmed by molecular testing) 
with AS. The results of this study suggest EEG findings are indicative of AS and, even in the 
absence of clinical findings, genetic testing should be completed when specific EEG patterns 
characteristic of AS are observed (Buoni, Grosso et al. 1999).  
 
Table 1-1. 2005: Clinical Features of Angelman Syndrome 
  
Frequently occurring (more than 80%) 
 Disproportionate growth in head circumference, resulting in microcephaly 
 Seizures 
 Abnormal EEG with characteristic pattern 
 
Associated (20%-80%) 
 Flat occiput Prognathia 
 Occipital groove Wide mouth 
 Protruding tongue Widely spaced teeth 
 Tongue thrusting Frequent drooling 
 Sucking/Swallowing disorders 
Excessive chewing/mouthing 
behaviors 
 Feeding problems Strabismus 
 Hypopigmented skin, light hair and eye color Hyperreflexia 
 Increased sensitivity to heat Wide based gait 
 Uplifted and flexed arm position during ambulation 
 4 
Differential Diagnosis 
Several conditions and phenotypes (Table 1-2) mimic the clinical features of Angelman 
syndrome resulting in the potential for misdiagnosis (Clayton-Smith and Pembrey 1992, Williams, 
Lossie et al. 2001). While a significant overlap in the clinical features exists between the conditions  
 
listed above, few reports of incorrect diagnoses exist. Of those reported, Angelman syndrome was 
mistaken for X-linked alpha-thalassemia (ATRX), ataxic cerebral palsy, and Rett syndrome, or 
vice versa (Clayton-Smith and Pembrey 1992, Williams, Lossie et al. 2001).  
Similar to Angelman syndrome, ATR-X is characterized by distinctive craniofacial 
features, such as small head circumference and widely spaced eyes. These patients also display 
hypotonia, severe developmental delays and intellectual disability which, often times, results in 
inability to walk independently or develop speech. In contrast to Angelman syndrome, patients 
with ATRX often exhibit anomalies of genitals, tented vermilion of the upper lip and thick or 
everted vermilion of the lower lip (Stevenson 1993). Aside from cytogenetic analysis, in families 
with an X-linked pattern of inheritance the diagnosis of Angelman syndrome can be excluded. 
Moreover, positive mutation testing for X-linked nuclear protein can help to delineate ATR-X 
from Angelman syndrome.  
Table 1-2. Conditions with Clinical Features Overlapping Angelman Syndrome 
Chromosome Disorders Single Gene Disorders Symptom complexes 
 22q13.3 terminal 
deletions 
 Del 15q12 (Prader-
Willi) 
 Dup 15q12 
 Del 2q22-q23 
 Others 
 Rett syndrome 
 X-Linked thalassemia 
syndrome (ATR-X) 
 Methylene 
tetrahydromfolate 
reductase deficiency 
 Gurrieri syndrome 
 Cerebral Palsy 
 Lennox-Gastaut 
syndrome 
 Static encephalopathy 
 Childhood Autism 
 Mitochondrial 
encephalopathy 
 Pervasic developmental 
disorder 
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Misdiagnosis has been shown to occur when patients with cerebral palsy (CP) exhibit AS-
like traits, including hypotonia, difficulty feeding and a happy demeanor. Some patients with CP 
exhibit an ataxic or unstable gain and tremulous movements. Magnetic Resonance Imaging of the 
brain of a patient with CP may be helpful by revealing mild atrophy. While positive results of the 
molecular studies described above offer a definitive diagnosis, it remains difficult to delineate 
between AS and CP when a patient exhibits only clinical symptoms (idiopathic AS).  
Of all the mimics mentioned in Table 1-2, Rett syndrome (RS) is the most common in 
female infants and toddlers. Schieffer et al. reported two cases in which female children with 
microcephaly, prominent lower jaw and protruding tongue were initially diagnosed with 
Angelman syndrome. Like AS, these patients exhibit muscular hypotonia, seizure, 
ataxic/dyspraxic gait, microcephaly and seizure disorder. In most cases RS is easily distinguished 
from AS given the higher cognitive ability of children with AS than those with Rett (Williams, 
Lossie et al. 2001). For example, in the case of Schieffer et al., having initially diagnosed 2 female 
children with AS, a revised diagnosis of Rett syndrome occurred after the patients showed 
regression in motor and verbal ability (Scheffer, Brett et al. 1990, Clayton-Smith and Pembrey 
1992). Since the publication of their report, mutations in the gene coding for DNA methyl binding 
protein (MECP2) has now been identified as the underlying cause of Rett syndrome and the use 
of molecular testing has made it easier to offer a definitive diagnosis. While it seems that RS only 
affects females, it is possible for male children to present with the disorder. However, considering 
the MECP2 gene locus is found on the X chromosome, unlike females, in males only one gene 
copy exists. Without a second normal copy of MECP2, males experience severe disability from 
the time of birth and die shortly thereafter. Still, more recent research has revealed mutations in 
other genes (i.e. CDKL5 and FOXG1) that may contribute to or be the cause of RS in a lower 
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number of patients. Taken together, physicians should be cautious diagnosing AS when they are 
presented with female children exhibiting the clinical features of AS but with regression of 
physical abilities. 
Molecular Basis of Angelman Syndrome 
Angelman syndrome results from a deficiency in the maternally derived homolog of the 
human chromosome 15q11-q13, the coding region that includes an E3 ubiquitin ligase, UBE3A 
(E6-AP) (Matsuura, Sutcliffe et al. 1997). By 1999, research had shown the disorder to be the first 
single gene disorder of the ubiquitination pathway and demonstrated a pattern of imprinting that 
was specific to the brain. Moreover, for the first time, scientific evidence was presented revealing 
the imprinting center of this region controlled genes that were necessary for long-term potentiation 
(LTP) (Jiang, Lev-Lehman et al. 1999). Encoded in the Ube3a gene are two RNA transcripts, the 
sense (maternally derived) and anti-sense (paternally derived). In 2003, Yamasaki et al. reported 
the sense strand of RNA was preferentially expressed in neurons but biallelic expression was 
observed in other glial cells (Yamasaki, Joh et al. 2003). Further research revealed UBE3A protein 
expression was tissue specific, with minimal protein concentration levels found in all neuron types 
of the hippocampus, hypothalamus, olfactory bulb, cerebral cortex, striatum, thalamus, midbrain 
and cerebellum in AS mice while a greater than 50% expression level of UBE3A was found in 
heart and liver tissues (Richard, Terry et al. 2010). 
Due to the preferential expression of the sense strand, any alteration (Table 1-3), the most 
common being a large (4 Mb) deletion, in the maternal gene results an absent or mutated version 
of the protein product leading to Angelman syndrome (Jiang, Lev-Lehman et al. 1999).  
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Diagnostic Molecular Testing 
Until the early 1990’s, Angelman syndrome was diagnosed clinically. That is, an individual 
was said to have AS if they met the diagnostic criteria mentioned above. However, more recently 
tests examining the genes of an individual have come online and allow physicians to offer a 
diagnosis of AS with near certainty. A common test used in the diagnosis of genetic abnormalities 
such as AS is a cytogenetic analysis. In this test, a karyotype of the patient’s chromosomes is 
made by pairing the chromosomes and ordering them from largest to smallest. In doing this, the 
geneticist can determine if the proper number of chromosomes are present and, in some cases, 
large deletions can be observed on a particular chromosome. Unfortunately, this test has poor 
resolution for small deletions of a particular allele which is common in Angelman syndrome. 
Methylation Testing 
Methylation patterns, specific to the parent of origin (maternal vs. paternal) can be detected 
using several different techniques. In general, lymphocytes from an individual’s whole blood 
sample are harvested and their DNA is isolated. Using techniques such as the methylation specific 
PCR test, the presence of methylation patterns contributed by both or either of the parents can be 
determined. Under normal circumstances a sample contains patterns specific to both the mother 
and the father when the UBE3A allele is examined. However, when the maternal methylation 
Table 1-3. Molecular Mechanisms of Angelman Syndrome 
Type Mechanism 
% Of the AS 
population 
Ia 4-Mb interstitial maternal del15q11-q13 65 – 75 % 
Ib Unbalanced translocation or inherited interstitial deletion < 1% 
IIa UPD maternal deficiency with normal parental chromosomes 3-5% 
IIb UPD with predisposing parental translocation <1% 
IIIa Imprinting mutation with deletion of IC 3%–5% 
IIIb Imprinting mutation without detectable deletion of IC 3%–5% 
IV Point mutations in UBE3A 4%–6% 
V AS phenotype with no identifiable molecular abnormality 10%–14% 
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pattern is missing, the patient is diagnosed with Angelman syndrome. While a definitive diagnosis 
of AS can be made using methylation testing techniques, further testing is still required to 
determine the particular molecular abnormality, such as, deletion size, uniparental disomy (UPD) 
or imprinting center defect (ICD) that exists.  
Fluorescent in situ Hybridization (FISH) 
The FISH test is used to determine presence or absence of a specific portion of DNA code. 
Complementary sequences to the UBE3A allele (a probe) are created using nick translation to add 
a nucleotide tag (-DigdUTP or Biotin-dUTP) and these probes allowed to hybridize with the DNA 
from cells fixed to a slide. The sample is then incubated with antibodies (anti-Dig or Avidin) and 
a fluorophore tag. Using fluorescent microscopy, the sample is examined for the presence of 2 
fluorophore tags which indicate two copies of UBE3A exist. However, if only one fluorescent tag 
is observed, the test has confirmed a deletion of one of the UBE3A alleles. To determine if AS was 
caused by a deletion, the results of this test are combined with the results of a methylation study. 
For example, if the methylation study is positive for the absence of the maternal methylation 
pattern and the results of the FISH are positive for the absence of one copy of UBE3A, the patient 
is said to have Angelman syndrome due to a deletion of the maternal allele. Similarly, if the FISH 
test is positive, but the paternal methylation pattern is missing, the patient is diagnosed with Prader-
Willi syndrome. Finally, when the methylation test is positive for Angelman syndrome but the 
FISH test is negative, further testing will be needed to determine if genetic abnormality is an UPD 
or ICD. 
Microsatellite Analysis 
 While methylation testing can be used to identify patients with UPD, large deletions and 
imprinting mutations, this testing cannot be used to determine which of the aforementioned genetic 
 9 
abnormalities are present in a patient with a positive methylation test. Therefore, further testing is 
warranted when patients present with the clinical features of AS, have a positive methylation result 
but are shown to exhibit negative FISH results. To determine if the underlying cause of AS is UPD, 
a blood sample is taken from both the patient and the parents to identify the inheritance of 
molecular polymorphisms. PCR primers unique to the UBE3A locus are used to amplify regions 
(PCR) of DNA which include microsatellites, which are simple sequence repeats commonly used 
as a genetic marker. These microsatellites are unique to the parent of origin and, when all the 
samples (patient, father and mother) are compared, inheritance can be determined. In the case of 
AS caused by UPD, only the paternal sequence will be observed in the patient’s sample. If the 
sample includes both maternal and paternal inheritance, ICD is inferred.  
UBE3A Sequencing 
 In approximately 15% of patients exhibiting the clinical features of AS, the testing 
mentioned above will not provide a definitive diagnosis and even more testing is required. With 
the recent advancements in gene sequencing, several different techniques can be used to determine 
the exact order of nucleotides of an individual’s DNA. Using these techniques, the specific 
sequence of the UBE3A gene can be determined and mutations in the genetic code identified. 
Several anomalous conditions can occur and include: 1) The introduction of polymorphisms that 
have no impact on the protein product. 2) Mutation of the genetic code that alters the structure of 
the protein product resulting in aberrant function. 3) The introduction of an early stop codon 
resulting in a truncated, non-functional protein product. 4) An addition or deletion of bases 
resulting in a mutated, non-functional protein product.  
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Idiopathic Angelman Syndrome 
 There is an estimated 10-14% of patients in which a molecular abnormality cannot be 
detected. However, these patients exhibit the same characteristic physical, behavioral and 
cognitive features of Angelman syndrome. These patients are diagnosed based on the clinical 
symptoms and with support provided by signature EEG patterns observed in 100% of patients 
(discussed above). 
Standard of Care in Treatment 
While people with Angelman syndrome have the potential for a normal life span, most 
individuals will have severe developmental delays, limited or non-existent speech and both fine 
and gross motor disability. There is no specific treatment of the syndrome but patients may benefit 
from physical, occupational and behavioral therapies. Special education techniques can be 
employed to maximize learning in this patient population. Treatment patients with AS receive most 
commonly consists of feeding supplementation, especially early in life, and the management of 
the medical and developmental issues, such as seizure and mobility. While several medications 
exist for the treatment of seizures, there is no medication currently available to treat the underlying 
cause of AS; the lack of a functional UBE3A protein.  
Neuropsychological Assessments 
 Few reports exist detailing the cognitive and behavioral performance of patients with 
Angelman syndrome on neuropsychological measures. As part of another research study testing 
the effect of two medications: betaine and folic acid, 20 children ranging in age from 5 months to 
10 years of age were tested. The neuropsychological measures employed were the Bayley Scale 
of Infant and Toddler Development, 2nd Edition (BSID-II) and the Vineland Adaptive Behavior 
Scales – Interview Edition (VABS). The results of this study revealed cognitive scores that fell 
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within the severe to profound range of cognitive impairment equating to the developmental age of 
3-17 months regardless of chronologic age. Moreover, severely delayed motor skills as well as 
delays in adaptive behaviors were also noted. It is important to point out, these children were 
unable to achieve standardized scores, therefore only raw scores (Table 1-4) could be used to 
describe their ability (Peters, Goddard-Finegold et al. 2004). Similarly, our laboratory recently 
completed a clinical study in which 25 children were evaluated using the BSID, 3rd Edition (BSID-
III) as well as the VABS (Table 3-2) and found severe deficits in cognition, motor ability and 
adaptive behaviors (Grieco, Ciarlone et al. 2014). The inability of this population to perform on 
these, and all other, standardized measures results in a “floor effect” and precludes our ability to 
accurately compare the severity of symptoms between individuals with AS and masks any changes 
that may be observed when a therapeutic is applied resulting in the potential to report false negative  
Table 1-4. Developmental Age Scores and Raw Score Breakdown According to Chronological 
Age 
Chronological Age (Months) Developmental Age (Months) Raw Score 
5 3 34 
15 6 61 
16 5 53 
23 7 68 
25 6 65 
26 7 70 
26 6 65 
26 7 68 
35 6 63 
40 7 67 
47 15 101 
49 9 76 
51 7 67 
51 9 76 
56 5 54 
67 14 94 
69 7 67 
95 17 108 
123 16 103 
The results shown by Peters et al. (2004) equate to profound cognitive deficits and raw scores below the 
minimum score required to calculate a standard score (a “floor effect”). However, these results do not 
reflect the ability of the patient or the severity of the patient’s symptoms. They only reveal the number 
of tasks the patient was willing to perform when asked. 
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results.  
The Biochemistry of UBE3A 
 UBE3A is a member of a class of proteins known as E3 ligases that are responsible for 
attaching an ubiquitin molecule to a specific protein target marking it for proteasomal degradation. 
The carboxy-terminal end of the UBE3A protein contains a 350 amino acid hect (homologous to 
E6-AP carboxy-terminous) domain. A segment of 100 amino acids at the end of the hect domain  
contain the catalytic site, which is responsible for transfer of ubiquitin molecules from the E3 
ligase to the substrate target. The substrate binding site is an 18 amino acid segment located in the 
central section of the UBE3A protein (Nawaz, Lonard et al. 1999). In the ubiquitination process, 
4 different proteins work in concert attaching molecules of ubiquitin to a protein targeted for 
proteasomal degradation (Figure 1-1).  
Initially, the UBE3A (E6-AP) protein was identified by its role in the ubiquitination of the 
E6 protein of the human papillomavirus promoting the degradation of p53 (Huibregtse, Scheffner 
et al. 1991, Huibregtse, Scheffner et al. 1991). However, further research has shown other targets 
exist including the HHR23A, which is involved in nucleotide excision repair and MCM7, part of 
the pre-replication protein complex (Kuhne and Banks 1998, Kumar, Talis et al. 1999) . Finally, 
 
Figure 1-1. Ubiquitination Consist of 4 Steps: 1) Activation of ubiquitin (Ub). 2) Transfer 
of ubiquitin to the E2 ubiquitin-conjugating enzyme. 3) A specific E3 ubiquitin ligase 
recognizes its target and catalyzes the transfer of the Ub molecule to the target substrate. 4) 
Ubiquitinated substrate is degraded via the proteasomal pathway. 
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Nuber et al. has shown E6-AP (UBE3A) is a target of itself and when ubiquitinated, the ligase is 
inactivated and then directed to the proteasome for degradation (Nuber, Schwarz et al. 1998).  
In addition to its role during proteasomal degradation, UBE3A also acts as a transcriptional 
activator of the human progesterone receptor and other members of this receptor superfamily. 
However, when Nawaz et al. examined mutant forms of human E6-AP, they showed 
transcriptional activation remained intact while proteasomal dysfunction was observed (Nawaz, 
Lonard et al. 1999). This research showed mutation in the hect domain, which causes catalytic 
dysfunction of the UBE3A, did not affect transcriptional activation. Their research suggests that 
Angelman syndrome is the result of a defect in the proteasomal degradation pathway. 
To determine where UBE3A resides within the brain, UBE3Ayfp reporter mice with a knock-
in mutation which fused a yellow fluorescent protein (YFP) to the C-terminus of UBE3A were 
created. Results of the study showed maternal UBE3Ayfp was expressed in high levels in the 
pyramidal cells of the CA3 region of the hippocampus as well as most other brain regions including 
the cortex, thalamus, olfactory bulb and cerebellum. In cell culture, UBE3A was detected in both 
the pre and postsynaptic densities (Dindot, Antalffy et al. 2008). Finally, quantification of both 
dendritic spine densities reveals significantly fewer spines on the hippocampal pyramidal cells of 
mutant mice when compared to wild type (Scott, Barbara et al. 2007). These results suggest the 
lack of a functional UBE3A protein results in structural abnormality of the dendritic spines and 
provides an explanation for the observed deficits in spatial memory in both mice and humans. 
The AS Mouse Model 
In 1998, the Angelman syndrome mouse model was created by replacing a 3kb genomic 
DNA fragment in exon 2. This mutation results in the deletion of one hundred of the most N-
terminal amino acids causing a shift in the reading frame and an inactive isoform of the UBE3A 
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protein. Neither wild-type (WT, m+/p+) nor paternally deficient (m+/p-) mice exhibit any 
phenotypic abnormalities on postnatal day 8. However, in mice with a maternal deficiency (AS, 
m-/p+) Jiang et al. observed a significant reduction in the total body weight, brain, cerebral cortex 
and cerebellum (Jiang, Armstrong et al. 1998). When these mice were tested on the accelerating 
rotating rod, the AS animals exhibited shorter latency to fall times than their WT littermates, the 
latter showed improvement over time as a result of motor learning. Associative fear conditioning 
is a test of learning in which mice associate a particular environment (context) with an aversive 
stimulus (foot shock). This form of learning has been shown to be hippocampal dependent and can 
be assessed by measuring the amount of time a trained animal freezes, a behavior characterized by 
a motionless, hunched posture. When AS mice were compared to WT animals, a 20% reduction 
in freezing was observed, suggesting mutant mice exhibit deficits in associative learning and 
memory. These results are supported by a decrease in field excitatory postsynaptic potentials 
(fEPSP’s) measured from the Schaffer collateral synapses in area CA1 while there was no 
difference between genotypes when input/output, fiber volley amplitude and paired pulse 
facilitation measures were analyzed. This suggests deficits in long-term potentiation are isolated 
to the post synaptic density. Taken together, this mouse model recapitulates the phenotypes 
observed in humans with Angelman syndrome.  
Clinical Research to Date 
The AS Natural History study is an ongoing longitudinal study of children and adults with 
AS examining the possible genotype-phenotype correlation(s) between the molecular subclasses 
of the disease (Gentile, Tan et al. 2010). The study is ongoing at the Children’s Hospital Boston 
as well as 5 other sites. Outcome data collected in this study includes annual medical histories, 
physical examinations, and neurodevelopmental assessments using the Bayley Scales of Infant and 
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Toddler Development (BSID-III), Vineland Adaptive Behavior Scales, Preschool Language Scale 
and the Aberrant Behavior Checklist. An electroencephalogram (EEG) is performed on each 
participant every other year as well. Currently the study has 200 participants enrolled representing 
children ages 2 to 5 years old. 
The AS Therapeutic Trial is an open label trial in AS children under the age of 5 years old 
to determine whether a one year treatment with the combination of Metafolin, vitamin B12, 
creatine and betaine can improve the neurodevelopment by promoting methylation and therefore 
expression of the normally silent paternal UBE3A. The neurodevelopmental assessments used in 
this study were the same as listed above in the AS Natural History Study. This clinical trial was 
completed and preliminary data suggests that the treatment regimen was not beneficial. 
Recently a multicenter, phase I trial examining the safety of Levodopa and Carbidopa was 
completed in a study cohort of 4 to 12 year old patients with AS. The same group of researchers 
are now planning a large phase II/III trial of the same medication. At the time this dissertation was 
written, the results of this study had not been published. 
More than 10 years ago, researchers observed positive effects after the administration of 
minocycline (MC) in mouse models of Huntington’s disease. The reversal of symptoms after the 
administration of MC in two separate studies led researchers to believe the drug could be used as 
a possible therapeutic agent (Chen, Ona et al. 2000, Yamamoto, Lucas et al. 2000). Since then 
several translational studies have been conducted and shown MC is well tolerated, safe and has 
the ability to improve the symptoms of several neurologic diseases including Parkinson’s disease, 
Huntington’s disease, multiple sclerosis and amyotrophic lateral sclerosis (Denovan-Wright, 
Devarajan et al. 2002, Blum, Chtarto et al. 2004, Thomas, Ashizawa et al. 2004, Kim and Suh 
2009). Studies testing the long-term use of MC to treat other diseases such as rheumatoid arthritis 
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and acne also show the drug is tolerated during long-term use, possesses neuroprotective 
characteristics and results in only minor adverse effects (Goulden, Glass et al. 1996, O'Dell, 
Blakely et al. 2001, Van Den Bosch, Tilkin et al. 2002, Bonelli, Heuberger et al. 2003, Utari, 
Chonchaiya et al. 2010). 
More recently, a retrospective study examining the documented side effects of MC in 50 
fragile X patients was completed. Participants of this study represented a mean duration of 
treatment of 3.5 months with a dosage ranging from 25mg to 200mg per day. The study results 
indicated, on average, a change in the participant’s behavior was observed after 3.5 weeks of 
treatment with MC. In most cases where a side effect was reported, it was mild gastrointestinal 
distress including loss of appetite and diarrhea that lasted for the first few days of treatment. 
Discoloration of the teeth is a side effect most feared in younger patients; however, there was no 
report of this side effect in this study population. This study showed there was no significant 
association between age and adverse effects. An improvement in language ability, attention, social 
communication and anxiety measured by the parent’s impression was reported. This study proves 
the use of MC to treat fragile X (and other neurologic disorders) in younger patients is reasonably 
safe and may result in behavioral improvements after a short treatment period (Utari, Chonchaiya 
et al. 2010). 
Tetracycline medications have been observed not only to have antimicrobial effects but 
also anti-inflammatory properties. This characteristic has been attributed to their ability to inhibit 
pro-inflammatory proteins such as matrix metalloproteinase (MMP’s). Since most 
neurodegenerative diseases have an inflammatory component, it stands to reason that MC could 
lessen the damaging effects of the inflammatory process by altering the biochemical pathways 
leading to neuronal damage.  
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Matrix metalloproteinases also play a role in the plasticity and morphology of dendritic 
spines (DS). Dendritic spines (DS) are small membranous protrusions extending from the dendrite 
of a neuron. A component of the synaptic junction, the DS receives excitatory signals from the 
synapse of an adjacent neuron. Proper number and morphology of DS’s is required for signal 
propagation resulting in normal brain function and cognition. A change in the number or 
morphology of DS’s has been implicated in the pathogenesis of several neurologic disorders 
(Kasai, Fukuda et al. 2010, Pan, Aldridge et al. 2010, Penzes, Cahill et al. 2011). Histologic 
examination of AS mice and human postmortem hippocampi revealed a decrease in the number of 
dendritic spines resulting in severe developmental deficits. However, after treatment with MC an 
increase in spine density was noted on excitatory neuronal dendrites leading to an improvement in 
cognition and behavior (Bilousova, Dansie et al. 2009, Grossman, Aldridge et al. 2010). Literature 
suggests MMP-7 is a key regulator of the extracellular matrix and which plays a vital role in the 
development of healthy, normally functioning DS’s (Bilousova, Rusakov et al. 2006, Ethell and 
Ethell 2007). Given MC interacts with MMP’s, a potential mechanism associated with MC is 
influencing morphology of DS’s and subsequent modification of synaptic function or overall 
connectivity.
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CHAPTER 2 
 
MINOCYCLINE INCREASES LONG-TERM POTENTIATION AND ASSOCIATIVE 
LEARNING IN THE ANGELMAN SYNDROME MOUSE MODEL 
Background 
Angelman syndrome is a rare genetic disorder occurring in 1/10,000 to 1/20,000 births 
(Clayton-Smith and Pembrey 1992, Petersen, Brondum-Nielsen et al. 1995, Steffenburg, Gillberg 
et al. 1996, Buckley, Dinno et al. 1998, Williams 2013). The disorder arises through the genetic 
or biochemical disruption of the maternal UBE3A allele, which when coupled with epigenetic 
silencing of the paternal UBE3A allele, gives rise to an absence of UBE3A protein in the central 
nervous system. Clinical manifestations of the syndrome vary in severity and include poor motor 
function, deficits in language and severe intellectual impairments. Patients with Angelman 
syndrome also exhibit characteristic behaviors including: fascination with water, hyper-
excitability (hyperactivity and hand flapping), inability to sense danger, tremor, lack of attention, 
reduced eye contact, attention-seeking behavior, and excessive laughter and smiling. 
Approximately 80% of children diagnosed with AS also suffer from seizure of various types and 
severity (Clayton-Smith and Laan 2003, Williams 2005, Pelc, Cheron et al. 2008). The diagnosis 
of Angelman syndrome is based on clinical evaluation and often confirmed using genetic testing. 
Several genetic mechanisms involving the maternal UBE3A gene result in the expression of the 
Angelman phenotype including a deletion, mutation, defect in the imprinting center or a 
uniparental disomy of the gene region containing UBE3A. Still, a small number of patients (15%) 
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exhibit the symptoms and behavioral characteristics of Angelman syndrome but no molecular 
mechanism can be detected. In addition to the clinical manifestations, many children with AS 
exhibit distinct EEG patterns that are specific to Angelman syndrome and are often used in the 
diagnosis of the syndrome when a molecular diagnosis cannot be confirmed (Laan and Vein 2005, 
Vendrame, Loddenkemper et al. 2012).  
Normal expression of the UBE3A gene (chromosome 15q11q12) results in the production 
of ubiquitin protein ligase E3 (UBE3A), an enzyme that is found in axons, dendrites and the soma 
of hippocampal neurons and is required for proteasomal degradation of intracellular proteins as 
well as for normal synaptic development (Dindot, Antalffy et al. 2008). Biallellic expression of 
UBE3A is seen in peripheral tissues; however, in neurons the maternal UBE3A allele is 
preferentially expressed while the paternal allele is imprinted and is silenced. Therefore any 
disruption of the maternal allele results in a dysfunctional or absent UBE3A protein resulting in 
Angelman syndrome (Chan, Clayton-Smith et al. 1993, Kishino, Lalande et al. 1997, Sartori, Anesi 
et al. 2008).  
The number and morphology of dendritic spines change throughout normal mammalian 
life. These dynamic characteristics contribute to the ability to form long-term memories. Abnormal 
spine shape and number has been implicated in several neurologic and neuropsychiatric disorders 
such as autism spectrum disorder, Fragile X syndrome, schizophrenia and Alzheimer’s disease 
(Kasai, Fukuda et al. 2010, Pan, Aldridge et al. 2010, Penzes, Cahill et al. 2011). Examination of 
pyramidal neurons of the hippocampus and cortex as well as cerebellar Purkinje cells from mice 
with Angelman syndrome revealed normal dendritic branching but altered dendritic spine 
development (Figure 2-1) including abnormal spine morphology, number and length (Dindot, 
Antalffy et al. 2008). Moreover, the autopsy of a 21-year old female with Angelman syndrome 
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revealed atrophy of cerebellar Purkinje cells. Golgi impregnation of pyramidal neurons in the 
human visual cortex showed a dramatic decrease in the dendritic arborization, abnormal 
morphology and decreased number of dendritic spines (Jay, Becker et al. 1991). The pathology 
described by these reports provides potential evidence for the cognitive impairment observed in 
Angelman syndrome.  
Figure 2-1. Abnormal Dendritic Spine Morphology of Cerebellum, Hippocampus and 
Cortex of Mice with Maternal Deficiency for UBE3A.  
A) Dindot et al. (2008) show AS mice exhibit abnormal dendritic spine morphology in 
cerebellum, hippocampus and cortex of AS mice. B & C) Quantification of dendritic spine 
number revealed a significant decrease in the spine density of area CA1 and layer 3-5 
pyramidal neurons. The length of dendritic spines of CA1 pyramidal neurons was also 
decreased in the AS mouse. D) Spine length was decreased in are CA1 pyramidal neurons as 
well. 
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Minocycline, a second-generation tetracycline antibiotic medication, is a small (495kDa), 
lipophilic molecule that readily crosses the blood brain barrier (O Ulgen, G Field et al. 2011). 
These characteristics allow minocycline to penetrate the central nervous system more readily than 
other members of the tetracycline family. The drug has a number of biologic effects other than 
anti-microbial activity including: 1) anti-inflammatory properties 2) anti-apoptotic properties 3) 
inhibition of proteolysis and 4) angiogenic properties (Garrido-Mesa, Zarzuelo et al. 2013). The 
administration of minocycline reduces the severity and progression of disease and in some cases 
prolongs the lifespan of animal models (Yong, Wells et al. 2004, Garrido‐Mesa, Zarzuelo et al. 
2013). For example, when minocycline was administered to the Fragile X mouse model, Bilousova 
et al. showed changes in the morphology of dendritic spines (Figure 2-2) of cultured hippocampal 
neurons from elongated (immature) to mushroom shaped (mature) accompanied by an 
improvement in spatial memory in a Fragile X mouse model (Bilousova, Dansie et al. 
2009). Studies of the effect of minocycline on humans with Fragile X syndrome revealed 
significant behavioral improvement in the subscale scores of the Aberrant Behavior Checklist-
Community, as well as the Visual Analog Scale and Clinical Global Impressions Scale scores 
(Paribello, Tao et al. 2010). Minocycline also decreases neuroinflammatory effects by down-
Figure 2-2. Minocycline Increased the Number of Mushroom 
Shaped Dendritic Spines in Cultured Primary Neurons from 
Fragile X Mice. 
Cultured primary neurons of Fragile X mice treated with 
minocycline showed increased number of mushroom shaped 
(mature) dendritic spines compared to untreated neurons (left). 
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regulating proinflammatory cytokines and microglial activation (Yrjanheikki, Keinanen et al. 
1998).  
Although the mechanism(s) of action is unclear, recent studies suggest minocycline may 
play an important role in modulating synaptic function. For instance, some have suggested 
minocycline may affect the activity of matrix metalloproteinase 9 whose targets include structural 
proteins of the extracellular matrix (ECM) as well as cell surface molecules and pericellular non-
matrix proteins. The catalytic property of these zinc-dependent (Zn2+) proteinases is therefore 
effective at regulating cell behavior in the context of synaptic plasticity (Sternlicht and Werb 
2001). Matrix metalloproteinases have also been shown to play a role in the plasticity and 
morphology of dendritic spines as well as aid in the development of healthy, normally functioning 
dendritic spines (Bilousova, Rusakov et al. 2006, Ethell and Ethell 2007). Minocycline’s positive 
neurologic effects and its interaction with MMP’s provides a possible mechanism for the observed 
changes in the morphology of dendritic spines and subsequent modification of synaptic function 
or overall connectivity (Blum, Chtarto et al. 2004). 
Considering minocycline’s low risk of adverse effects, low chance of forming antibiotic 
resistance, potential to normalize synaptic structure and its ability to improve behavioral 
performance in humans led us to posit that administering minocycline to mice with Angelman 
syndrome may ameliorate the CNS symptoms associated with AS, improve behavioral 
performance and restore synaptic function. 
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Materials and Methods 
Ethics Statement 
Animal testing procedures were approved by the Institutional Animal Care and Use 
Committee at the University of South Florida and complied with the National Institutes of Health 
guidelines for the care and use of laboratory animals (Protocol ID number IS00000479). 
Mouse Model of Angelman Syndrome 
Mice with a UBE3A null mutation have been described previously. Female paternal 
deficient mice (Jackson Labs, Bar Harbor, ME) were bred with C57BL/6 wild type male mice to 
produce F1 generations of maternal deficient hybrid mice and wild type littermate controls as 
previously described (Jiang, Armstrong et al. 1998). Animals were kept on a 12-hour light/dark 
cycle and food and water was provided ad libitum. All experiments were performed during the 
light cycle with each treatment group consisting of a minimum of seven male, 2-3 month old 
animals. 
General Activity 
The open field test was used to measure activity. As previously described, mice were 
allowed to explore a 40 x 40 cm acrylic chamber for 15 minutes (Daily, Nash et al. 2011). Behavior 
was monitored via video tracking software (ANY-maze, Stoelting, Wood Dale, IL) and measures 
of movement and distance traveled were recorded. As a measure of anxiety, the amount of time 
spent in the center of the apparatus was compared to the amount of time spent in the perimeter 
(along the walls). The elevated plus maze was also used to assess anxiety. The animals were placed 
in a plus-shaped maze elevated 40 cm above the table top and consists of 2 open arms and 2 closed 
arms. Each mouse was placed in the apparatus and allowed to explore for 5 minutes. Increased 
time spent in the open arm over the closed arm indicates reduced anxiety.  
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Motor Performance 
The accelerating rotorod was used to assess motor coordination and motor learning (Ugo 
Basile, Italy). As previously described, mice were placed on a 3 cm diameter rotating rod with an 
initial speed of 4 RPM accelerating to 40 RPM over 300 seconds (van Woerden, Harris et al. 2007, 
Daily, Nash et al. 2011). The latency to fall off the rod for each animal was recorded for 4 trials 
over 2 consecutive days.  
Associative Fear Conditioning 
To assess hippocampal function and memory, mice were trained by placing the animals in 
a 25 x 25 cm context with a wire grid floor surrounded by a sound attenuated chamber. They were 
allowed to explore for 120 seconds prior to the initiation of the conditioned stimulus (CS), a 30-
second, 90db tone. After 28 seconds, the unconditioned stimulus (US), a 0.8mA foot shock, was 
administered for 2 seconds. After a 90 second inter-stimulus interval, a second pairing was initiated 
followed by another 90 second resting period before returning the animals to their housing. 
Contextual fear conditioning was conducted 24 hours after the training in the same chamber with 
no CS for 180 seconds. The amount of time the animal spent freezing was recorded by behavioral 
monitoring software (ANY-maze, Stoelting, Wood Dale, IL). After the contextual trial, the 
chamber was altered by the addition of a novel scent, floor texture and wall coverings. Cued fear 
conditioning was carried out by allowing the mice to explore the novel context for 180 seconds 
after which, a conditioned stimulus, identical to training, was introduced for another 180 seconds. 
Freezing behavior was recorded during both periods of time using the same behavioral monitoring 
software mentioned above. Freezing behavior was defined as immobility for a period of at least 2 
seconds.  
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In Vivo Dendritic Spine Analysis 
After 28 days of minocycline injection, brains were harvested and bisected. One 
hemisphere per animal was immersed in 1 ml per gram of tissue of Golgi impregnation solution 
(Rapid Golgi Staining Kit, FD Neurotechnologies, Columbia, MD) and stored at room temperature 
free from exposure to light. The impregnation solution was exchanged after 24 hours of immersion 
and tissue was incubated for a period of 10 to 14 days. The brain tissue was transferred to solution 
C for 72 hours. Each brain was then sectioned to a thickness of 100μm using a vibratome 
(VT1000S, Leica, Buffalo Grove, IL) and mounted on gelatin-coated slides. After a drying period, 
slides were rinsed in Milli-Q water, stained with a mixture of solution D and E, dehydrated and 
cleared with xylene according to the manual. Coverslipping was achieved using undiluted 
Permount (Fisher Scientific, Pittsburg, PA).  
Using bright field microscopy (Axioplan 2, Zeiss, Pleasanton, CA), Z-stack images were 
taken of 20 µm lengths of 2 apical dendrites of 10 area CA1 pyramidal neurons at 100x 
magnification and analyzed using RECONSTRUCT software (http://synapses.clm.utexas.edu) as 
described by Risher et al. for spine density and morphology by a blinded analyst (Risher, 
Ustunkaya et al. 2014).  
Hippocampal Slice Preparation and Electrophysiology 
Euthanasia was achieved by rapid decapitation after which the brain was placed in ice-cold 
cutting solution (110mM sucrose, 60mM NaCl, 28mM NaHCO3, 1.25mM NaH2Po4, 7mM MgCl2, 
0.5mM CaCl2, 0.6mM sodium ascorbate, and 5mM D- glucose, pH 7.4). The brain was sectioned 
horizontally into 400 μM slices and allowed to equilibrate in a mixture of 50% cutting and 50% 
ACSF solution for 15 minutes. Slices were then transferred to artificial cerebral spinal fluid 
(ACSF, 125mM NaCl, 2.5mM KCl, 1.25 NaH2PO4, 28 mM NaHCO3, 1.0 MgCl2, and 10 mM D- 
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glucose, pH 7.3) at room temperature for 30 minutes prior to placement in the interface chamber. 
Supported by nylon mesh, slices were bathed in ACSF saturated with 95% O2 and 5% CO2.  
As previously described by Weeber et al., pyramidal neurons of area CA3 were stimulated 
with a bipolar electrode and recordings were obtained via glass microelectrode filled with ACSF 
(1-4 mΩ resistance) from area CA1 pyramidal neurons. Theta-burst stimulation (TBS), 5 trains of 
four pulses at 200Hz separated by 200 ms and repeated a total of 6 times with a 10 second intertrain 
interval, were used to evoke CA1 long-term potentiation (LTP). Stimulus intensity was adjusted 
so fEPSPs (field excitatory postsynaptic potentials) slopes were ≤50% of the maximum stimulus 
intensity as determined from the input/output curve. Potentiation was measured as the increase in 
the mean fEPSP following stimulation normalized to the mean fEPSP for the baseline recording. 
Results were obtained from slices that exhibited a stable baseline for 20 minutes prior to the 
stimulus delivery (Weeber, Beffert et al. 2002).  
Results 
Minocycline at Lower Dosage Improves Contextual Learning but not Motor Ability 
To date, the activity level of naive AS mice has not been described. However, Daily et al. 
shows similar amounts of activity between WT and AS transgenic mice (Daily, Nash et al. 2011). 
Since hyper or hypo-active behavior can affect the results of behavioral testing such as fear 
conditioning, general activity levels of these AS mice were assessed using the open field test. Mice 
were placed in the center of a 40cm x 40cm acrylic chamber and allowed to explore freely for a 
period of 15 minutes. The distance traveled by the animal is recorded by computer tracking 
software (Anymaze, Stoelting, Wood Dale, IL). We observed no significant differences (F(5,59) 
= 1.461, p = 0.218) in the distance traveled between either genotype or treatment groups (Figure 
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2-3). These results suggest minocycline does not affect the overall activity of these mice and any 
subsequent behavioral differences are not the result of hyper- or hypo-activity.  
Patients with AS often exhibit tremor, ataxia and general motor incoordination. Similarly, 
UBE3A maternal deficient (AS) mice have been shown to exhibit deficits in motor ability evident 
by shorter latency to fall times when compared to wildtype (WT) mice (Jiang, Armstrong et al. 
1998). To test the effect of minocycline on motor function, 2 cohorts (22.5 and 45 mg/kg dosage) 
of 4 treatment groups (WT, WT treated, AS and AS treated) where subject to the rotorod test (Ugo 
Basile, Varese, Italy). All groups exhibited improvement in latency to fall over 8 trials which is 
evidence of intact motor learning (Figure 2-4). However, between group comparisons revealed 
significant differences, F(3,31) = 6.248, p = 0.0022, existed only between genotypes (AS and WT) 
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Figure 2-3. Similar Amounts of Activity was Observed Between 
Genotypes and Treatment Groups. 
 
No significant differences between any groups were observed in the 
mean distance traveled during 15 minutes of open exploration. These 
data suggest the activity level for all groups is similar and results of 
other behavioral tests are not affected by hypo or hyper-activity. 
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and a treatment effect was not observed. These results suggest that while motor learning remains 
intact after receiving minocycline treatment, treatment with the antibiotic does not improve the 
motor coordination of these AS mice.  
In addition to motor disability, patients with AS also exhibit deficits in learning ability. To 
test the effect of minocycline on associative learning, AS and WT mice were subject to the fear 
conditioning paradigm. Fear conditioning is a form of associative learning in many species of 
animals and consists of two distinct forms of learning, contextual and cued. During cued fear 
conditioning, the animal is presented with an auditory stimulus just prior to an aversive stimulus 
(a foot shock). The association of the auditory stimulus with the aversive stimulus has been shown 
to be resistant to hippocampal lessoning. A fear response, in the form of a motionless, crouching 
posture (freezing) was assessed for 3 minutes in the original context using computer tracking 
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A minimum of eight animals per group were tested on the accelerating rotating rod in two 
cohorts, those animals receiving a 45mg/kg or 22.5mg/kg dose (IP injection) with WT 
littermates receiving saline injections as a control. As expected, AS mice had significantly 
shorter latency to fall times than WT animals. Moreover, increases in latency to fall times 
were not observed after treatment with either dosage of minocycline. 
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software (Anymaze, Stoelting, Wood Dale, IL). In this experiment, freezing behavior was assessed 
for 6 minutes (3 minutes of silence followed by 3 minutes of tone) in a neutral context. We 
observed no differences in freezing either between genotypes or treatment groups in these 2 
cohorts. 
During contextual learning 
the animal associates its 
environment (the context) with an 
aversive stimulus (a foot shock). 
This type of conditioning has been 
shown to be dependent on proper 
function of the amygdala and 
hippocampus. As described above, 2 
cohorts (differing doses) were 
examined and revealed no change in 
the time spent freezing when WT 
saline treated mice were compared to 
WT mice receiving either 22.5 or 
45mg/kg of minocycline (Figure 2-
5). However, AS mice treated with 
the lower dosage of minocycline 
exhibited a significant increase in 
freezing (F(3,27) = 3.717, p = 0.025) 
as compared to AS mice receiving 
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Figure 2-5. Minocycline Treatment Significantly 
Increased the Amount of Freezing in AS Mice.  
 
A) No significant differences were observed between 
groups when mice were treated with 45mg/kg of 
minocycline. B) A significant increase in freezing 
(F(3,27) = 3.717, p = 0.025) was observed in AS mice 
that received 22.5 mg/kg of minocycline when 
compared to those receiving saline.  
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saline when placed back into the training context. These results suggest minocycline does not have 
an effect in animals with intact contextual learning. However, the deficits in hippocampal 
dependent learning associated with the AS mouse can be overcome after treatment with 22.5mg/kg 
of minocycline but not 45mg/kg. This suggests a non-linear relationship exists between dosage 
and the effects on hippocampal dependent learning.  
Treatment with Minocycline Results in Increased LTP Response of CA1 Pyramidal Neurons 
 Hippocampal LTP is a well established method of measuring synaptic plasticity. Severe 
deficits in LTP of the CA1 pyramidal neurons after high-frequency stimulation have previously 
been shown in the maternal deficient AS mouse model (Jiang, Armstrong et al. 1998, Weeber, 
Jiang et al. 2003, van Woerden, Harris et al. 2007, Daily, Nash et al. 2011, Filonova, Trotter et al. 
2014, Grieco, Ciarlone et al. 2014, Hethorn, Ciarlone et al. 2015). We recorded 
electrophysiological responses (Figure 2-6) from neurons in area CA1 to determine if changes in 
synaptic function existed in conjunction with the observed changes in freezing behavior after 
treatment with minocycline. The input/output relationship was evaluated by comparing fEPSP 
slope to fiber volley (FV) amplitude across a range of stimulus intensities, from 1 to 15 mV. 
Omnibus ANOVA and Tukey’s post hoc test results revealed statistically significant (F(3,106) = 
3.688, p = 0.0144) differences both WT and AS mice that had received 45mg/kg of minocycline 
and mice receiving saline vehicle injections (Figure 2-6A). When the FV and fEPSP slope was 
compared to the stimulation intensity separately, a significant increase (F(3, 115) = 2.919, p = 
0.0372) in presynaptic activation (Figure 2-6B) was observed in AS control mice (saline vehicle 
injected). Moreover, a significant decrease (F(3,115) = 6.737, p = 0.0003) in post-synaptic 
activation (Figure 2-6C) was observed for both AS and WT mice treated with minocycline 
compared to mice treated with saline vehicle. A paired  
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Figure 2-6. The Administration of Minocycline Alters the Postsynaptic Response to 
Stimulus and Results in Increased LTP. 
A) Input/output was evaluated by comparing fEPSP slope to fiber volley (FV) amplitude across a range of 
stimulus intensities (1-15 mV). Statistical analysis revealed a significant, F(3,106) = 6.314, P = 0.0144) 
difference between the WT and AS mice that had received 45mg/kg of minocycline and those that had received 
saline, but not between genotypes. B & C) The FV amplitude and fEPSP slope were then compared to the 
stimulus intensities separately and revealed a significant, F(3,115)) = 2.919,  p = 0.0372 and F(3,115) = 6.737, 
p = 0.0003 respectively, difference in presynaptic activation in the AS mice receiving saline when compared 
to all (WT, WT MC, AS MC) of the other groups. Moreover, postsynaptic activation was reduced when both 
WT and AS mice received treatment with minocycline. D) A paired-pulse facilitation protocol (20-300ms) was 
used test short-term presynaptic plasticity and revealed no significant differences between any of the groups. 
E) LTP was induced using a theta-burst stimulation protocol. Significant reductions (F(2,259) =7.719, p = 
0.0006) in the induction of LTP was observed in the slices of AS mice receiving saline treatment. However, 
slices from AS mice treated with of minocycline showed an increase in LTP, to the level of WT, resulting in 
the recovery of the LTP deficit associated with these AS mice. F) Slices from WT animals treated with 45mg/kg 
of minocycline did not show a significant increase in LTP over WT mice treated with saline. 
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pulse facilitation protocol (20 to 300ms) was used to test short-term presynaptic plasticity and no 
significant differences (Figure 2-6D) was seen between any of the groups. These results suggest 
pre-synaptic hyperactivity may contribute to the synaptic dysfunction observed in the AS mouse 
model. Further, the pre and post-synaptic response to stimulus can be attenuated with the 
administration of minocycline.  
LTP was induced using our previously described TBS stimulation. Consistent with 
previously published results, we found that AS mice receiving saline treatment exhibited 
significant deficits in high frequency stimulation (HFS) induced LTP when compared to WT 
littermate controls (Figure 2-6E & F). Interestingly, we found both treatment groups, WT MC and 
AS MC, exhibited LTP measures that significantly (F(3,339) = 31.79, p <0.0001) exceed those of 
the AS control mice and restored the LTP measures of AS treated mice to the level of WT controls 
after TBS.  
Minocycline Recovers the Dendritic Spine Density Defect in the AS Mouse Model 
 Many forms of severe cognitive impairment have been tied to pathologic alterations in 
dendritic spine structure and distribution (Smrt and Zhao 2010). For example, previous AS 
research shows AS mice exhibit reduced dendritic spine density in area CA1 as well as layer 3-5 
pyramidal neurons. This pathology underlies the aberrant synaptic function observed in the AS 
mouse model (Dindot, Antalffy et al. 2008, Hethorn, Ciarlone et al. 2015). However, when spine 
density is restored, a recovery of associative fear conditioning and synaptic plasticity deficits is 
observed (Hethorn, Ciarlone et al. 2015). Consistent with previous research, histologic analysis of 
the apical dendrites from CA1 area Golgi impregnated pyramidal neurons of these mice reveal a 
significant reduction (F(5,38) = 5.538, p = 0.0008) in the spine density of AS mice when compared 
to WT littermate controls (Figure 2-7A & B). Interestingly, the treatment of AS mice with either  
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Figure 2-7. Minocycline Treatment Increases the Mean Density of Dendritic Spines in the 
AS Mouse.  
A) Light micrograph images from Golgi impregnated hippocampal pyramidal neuron from WT 
and AS mice treated with saline, 22.5 and 45mg/kg of minocycline (Scale bar = 10µm). B) 
Quantification of the dendritic spines of apical dendrites of pyramidal neurons located in area 
CA1 of the hippocampus. The spine density of saline vehicle treated mice is significantly reduced 
compared to WT saline treated animals. Both treatments, 22.5 and 45mg/kg of minocycline, 
rescued the spine density deficit of the AS mouse (F(5,38) = 5.538, P = 0.0008). C) Significant 
increase in the total number of mushroom shaped (mature) dendritic spines was observed in WT 
mice treated with 45mg/kg of minocycline (F(5,38) = 3.687, p = 0.0092). 
 34 
22.5 or 45mg/kg of minocycline rescued the defect by significantly increasing (F(5,38) = 5.538, p 
= 0.0008) the mean spine density to the level of their WT littermates. This suggests minocycline 
may increase dendritic spine density and therefore the number of functional and/or active synapses. 
 Because of the role dendritic spines play in synaptic function, altered spine morphology 
has a significant impact on the function of the neural network as a whole (Smrt and Zhao 2010). 
For instance, abnormal spine morphology has been observed in several conditions such as autism, 
Rett and Fragile X syndromes. To determine minocycline’s effect on spine morphology, we used 
the rapid analysis method described by Risher et al. and the freely available software, 
RECONSTRUCT (http://synapses.clm.utexas.edu), to analyze the apical dendrites from CA1 area 
Golgi impregnated pyramidal neurons of these mice (Risher, Ustunkaya et al. 2014). Results of 
our analysis reveal no significant differences in the morphology of the animals examined (n = 5 
mice per group, 20 neurons per group, 2 apical dendrites per neuron) with one exception. A 
significant increase in mushroom shaped (mature) spines was observed (Figure 2-7C) when WT 
animals were treated with 45mg/kg of minocycline. These data suggest minocycline may have 
ability to influence the development of more mature synapses (mushroom shaped spines) resulting 
in improvements in synaptic function.  
Discussion 
Defects in synaptic plasticity caused by the lack of a functioning UBE3A protein has been 
suggested as the core cause of impairment in the AS mouse. Unfortunately, histologic study of the 
brain from 1 human female with AS revealed alteration in the morphology and density of dendritic 
spines (Jay, Becker et al. 1991). However, this does provide supportive evidence that aberrant 
synaptic function is the underlying cause of the learning deficits associated with AS in humans 
and mice. Factors that contribute to proper synaptic function include, but are not limited to, the 
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structure and morphology of dendritic spines, the transmission of neurotransmitter, the density and 
function of glutamate receptors (AMPA and NMDA). 
Results of our behavioral testing show that while the activity level of each genotype and 
treatment group was similar, the AS mice treated with a lower dose (22.5mg/kg) of minocycline 
showed greater associative learning than saline vehicle controls. Integration of sensory cues 
combined with somatosensory processing via the hippocampus suggest that a global increase in 
synaptic function is likely to contribute to the correction of the associative learning defect. Further 
support is provided by increased LTP in AS mice.  
In hippocampal primary cell culture from mice with Fragile X, normalization of morphology, 
from filopodial to mushroom shaped, was reported when minocycline was applied (Bilousova, 
Dansie et al. 2009). Many have shown the cellular basis of learning and memory requires the 
dendritic spines of pyramidal neurons to undergo structural remodeling. While the relationship 
between remodeling and plasticity, such as LTP, has not yet been determined, most agree the 
normalization of dendritic spine density results in increased LTP (Yuste and Bonhoeffer 2001, 
Matsuzaki, Honkura et al. 2004). Consistent with the results of Bilosova et al., histological analysis 
of Golgi impregnated hippocampal slices of these AS mice revealed a dramatic reduction in the 
mean density of dendritic spines of area CA1 pyramidal apical dendrites when AS mice were 
compared to WT mice. Further, when AS mice were treated with either 22.5 or 45mg/kg of 
minocycline, a complete recovery of the spine deficit was observed. To assess the spine 
morphology in these AS mice, we used computer software to measure the length and width of 
spines and saw no differences in the total number of any one specific morphology (mushroom, 
filopodial, long thin, thin, stubby or branched) between groups.  
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These data suggest the observed changes in behavior (increased freezing time) may be due to a 
normalization of the overall dendritic spine density rather than a change from one spine 
morphology to another in the area CA1 pyramidal neurons of these AS mice.  
Interestingly, minocycline has been shown to chelate Ca2+, inhibit NMDA-induced cytosolic 
Ca2+ concentrations and, in the presence of Ca2+, deprotonated minocycline may form membrane 
bound ion channels (Antonenko, Rokitskaya et al. 2010, Garcia-Martinez, Sanz-Blasco et al. 
2010). Moreover, Gonzalez et al. report a 20% and 30% decrease in inward Na+ and Ca2+ current 
in cultured rat hippocampal neurons. Also, glutamate-evoked elevations of Ca2+ were reduced by 
40% at high but not low concentrations of minocycline (González, Egea et al. 2007). These reports 
suggest that minocycline alters the membrane potential, which may result in hyperpolarization of 
the neuron. While the exact mechanism is still unknown, these reports provide a possible 
explanation for the significant decrease in FV amplitude and fEPSP slope observed in these AS 
mice when treated with the higher dose of the drug. This may also underlie the increase variation 
in AS mice treated with 45mg/kg of minocycline.  
Conclusion 
 Minocycline is a widely used antibiotic medication with a long history of safety and 
tolerability in humans. Several studies have shown the drug to improve learning and memory and 
protect neurons from excitotoxicity. We show the treatment of AS mice with minocycline results 
in normalization of dendritic spine density as well as an increase in LTP. While a specific 
mechanism is unknown, these effects provide a potential explanation for a dose dependent increase 
in associative learning in the AS mouse model. These results show the promise of minocycline for 
use as a potential therapeutic for Angelman syndrome.  
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CHAPTER 3 
 
MINOCYCLINE TREATMENT IS WELL TOLERATED AND IMPROVES ADAPTIVE 
BEHAVIORS IN CHILDREN WITH ANGELMAN SYNDROME 
Background 
Consistent with the initial description by Dr. Harry Angelman, children with AS present 
clinically with physical features such as microcephaly and a puppet like gait as wells as profound 
developmental delays and little vocal communication ability (Angelman 1965, Barry, Leitner et 
al. 2005, Williams 2005, Horsler and Oliver 2006, Williams 2010). While these patients exhibit a 
happy demeanor and easily provoked laughter, this syndrome also consists of other manifestations 
including hyper-excitability, poor motor function, and delays in adaptive behaviors. Furthermore, 
patients with AS exhibit EEG patterns specific to the syndrome, and when present in the 
appropriate clinical context, help in diagnosing the syndrome earlier. Finally, 90% of children 
diagnosed with AS suffer from seizure of various types and severity (Boyd, Harden et al. 1988, 
Laan, Renier et al. 1997, Clayton-Smith and Laan 2003, Laan and Vein 2005, Williams 2005, Pelc, 
Boyd et al. 2008, Pelc, Cheron et al. 2008, Vendrame, Loddenkemper et al. 2012, Vendrame, 
Loddenkemper et al. 2012). 
In nearly all cases Angelman syndrome results from the disruption of a single gene, UBE3A 
(Kishino, Lalande et al. 1997, Williams 2009). Previous research in both the AS mouse model and 
humans with AS show no gross morphology changes in the brain. However, the absence of the 
protein product, UBE3A, a E3 ubiquitin ligase, results in the accumulation of regulatory proteins, 
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such as arc and ephexin 5 in the postsynaptic density, which is believed to cause abnormal dendritic 
spine morphology (filopodial) and density in hippocampal pyramidal neurons leading to aberrant 
synaptic function (Scott, Barbara et al. 2007, Margolis, Salogiannis et al. 2010). These alterations 
in spine morphology and synaptic function in neurons provides an explanation for the severe 
behavioral and cognitive manifestations of the syndrome. Our laboratory has recently reported the 
application of Reelin, a protein shown to increase dendritic spine density, enhanced cognition in a 
mouse model (Rogers, Rusiana et al. 2011). Further, other researchers have recently reported the 
recovery of the cognitive and behavioral deficits associated with AS and even the commencement 
of UBE3A protein production when certain therapeutics such as UBE3A viral vectors and 
topoisomerase inhibitors were applied (van Woerden, Harris et al. 2007, Daily, Nash et al. 2011, 
Huang, Allen et al. 2012). It stands to reason then, a therapeutic with the ability to normalize the 
aberrant synaptic function underlying AS could ameliorate the severity of symptoms. 
Minocycline hydrochloride (MC) is a small (495 kDa), lipophilic, second-generation 
tetracycline antibiotic medication that readily crosses the blood brain barrier (Ulgen, Field et al. 
2011). These characteristics allow minocycline to penetrate the central nervous system more 
readily than other members of the tetracycline family (Macdonald, Kelly et al. 1973). As with the 
aforementioned therapies, minocycline has been shown to recover synaptic dysfunction through 
the modulation of dendritic spine structure by reducing the activity of matrix metalloproteinases 
(Bilousova, Dansie et al. 2009). Previous research has shown the incubation of neuronal cultures 
with MMP-9 altered dendritic spine shape and number. Moreover, increases in both protein level 
and activity of the MMP’s occurs in models of epilepsy, which is prevalent in the AS population 
(Pelc, Boyd et al. 2008). Further, minocycline changes the morphology of dendritic spines in 
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hippocampal neurons from elongated (immature) to mushroom-shaped (mature), ultimately 
rescuing the synaptic defect and improving spatial memory (Bilousova, Dansie et al. 2009). 
Interestingly the application of minocycline has been shown to act on numerous other 
aspects of the CNS. The drug has been shown to be neuroprotective, anti-apoptotic, and anti-
inflammatory (Thomas and Huganir 2004, Kernt, Neubauer et al. 2010, Mehrotra, Pecaut et al. 
2014). Beyond this, minocycline can positively alter the AMPA-type glutamate receptor (Chen 
and Manev 2011, Jin, Schlesinger et al. 2012), metabotropic glutamate receptor 1 and 5 (Fujita, 
Ishima et al. 2008, Greer, Hanayama et al. 2010) and NMDA receptor function (Goni-Allo, Ramos 
et al. 2005, Greer, Hanayama et al. 2010). Metabotropic glutamate receptors, AMPA receptors and 
NMDA receptors are known to be important in overall neuronal function and contribute to the 
synaptic plasticity defect in the AS mouse model (Quinlan, Philpot et al. 1999, Weeber, Jiang et 
al. 2003, Fujita, Ishima et al. 2008, Pignatelli, Piccinin et al. 2014). 
Minocycline has also been used as a treatment of other human cognitive disorders. For 
example, when MC was administered to patients with Fragile X syndrome (FRX), significant 
behavioral improvement in the subscale scores of the Aberrant Behavior Checklist-Community, 
as well as the Visual Analog Scale and Clinical Global Impressions Scale scores were reported 
with only minor adverse effects observed (Paribello, Tao et al. 2010). Studies of the drug’s effect 
on degenerative neuropathology (e.g., Alzheimer’s and Parkinson’s disease, Amyotrophic Lateral 
Sclerosis) have shown the administration of minocycline reduces the severity and progression of 
disease and, in some cases, prolongs the lifespan of animal models (Yong, Wells et al. 2004, 
Garrido-Mesa, Zarzuelo et al. 2013). 
Preclinical electrophysiological studies were carried out in a mouse model of AS 
(RRID:IMSR_JAX:004477) after 21 days of minocycline treatment. We found a full recovery of 
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the synaptic plasticity defect normally observed in the AS mouse model (Figure 3-1) (van 
Woerden, Harris et al. 2007). We, and others, have shown a reduction in synaptic plasticity in the 
hippocampus, cerebellum and visual cortex in the AS mice (Quinlan, Philpot et al. 1999, Weeber, 
Jiang et al. 2003, Egawa, Kitagawa et al. 2012). Therefore, recovery of the synaptic plasticity 
defect was a significant finding for this therapeutic.  
The precise mechanism of minocycline, beyond its antibacterial mechanism, is unknown. 
However, this has not precluded the investigation of minocycline (with associated benefit) on 
human neurological diseases such as Alzheimer’s, Parkinson’s, Stroke, traumatic brain injuries 
and Fragile X syndrome (Yong, Wells et al. 2004, Paribello, Tao et al. 2010, Garrido-Mesa, 
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Figure 3-1. Minocycline Restores the Synaptic Plasticity Defect in the AS Mouse 
Model.  
3-month-old UBE3A maternal deficient (AS) mice (129Sv/Ev background) show 
increase in long-term potentiation (LTP) after 21 days of treatment with minocycline. 
Field extracellular postsynaptic potentials (fEPSPs) were recorded and their slopes are 
conveyed as a percentage of the pre-theta burst stimulation (TBS) baseline. 
Representative traces before (bold) and 30 minutes after TBS are shown for saline treated 
(control) and minocycline treated AS mice. 
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Zarzuelo et al. 2013). The results of the above mentioned studies led us to posit that administering 
minocycline to patients with Angelman syndrome may ameliorate the central nervous system 
symptoms associated with the syndrome and improve behavioral performance. Here, we report the 
changes in symptom severity, cognition, and adaptive behavior after a sample of 25 children with 
Angelman syndrome were administered minocycline for 8 weeks. The objective of this study was 
to evaluate the tolerability of minocycline in children with AS and provide preliminary 
neuropsychological and electroneurophysiology data. 
Methods 
Study Design 
This study took place at the University of South Florida and was approved by USF’s 
Human Research Protection Program’s Institutional Review Board (Pro00004716). The USF IRB 
issued a waiver of assent; however written informed consent was obtained from both the mother 
and father of each participant. Since no previous research existed showing how children with AS 
would respond to minocycline, statistical methods could not be employed to determine sample 
size. Therefore, human subject protections mandated a single arm open-label study design be 
implemented with no placebo control. After baseline testing (T1), 25 children with AS were 
prescribed minocycline for 8 weeks. No change in the participant’s medication regimen was 
required for inclusion in the trial. The time course and dosing was determined from previous 
research in which children with FRX were administered minocycline (Paribello, Tao et al. 2010). 
The study participants were evaluated again after 8 weeks of treatment (T2) and 8 weeks after 
minocycline was discontinued (T3).  
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Recruitment 
Participants of this study were recruited through the websites of Angelman parent 
organizations and clinicaltrials.gov. Children with Angelman syndrome, who met the inclusion/ 
exclusion criteria were pooled and participants were selected at random using a computer 
generated randomization schedule (SAS, Cary, NC). To minimize the chance of screen failure, 
parents were required to have their child’s primary care provider or neurologist complete a short 
questionnaire attesting the child met the inclusion criteria and provide an indication of the severity 
of the child’s disability due to Angelman syndrome. Inclusion criteria included: 1) A molecularly 
confirmed diagnosis of Angelman syndrome. 2) Age between 4 to 12 years old at the time of 
recruitment. 3) A CGI-S score of 4 or greater indicating at least moderate severity of symptoms. 
4) An acceptable surrogate capable of providing consent on the participant’s behalf. 
Exclusion criteria included: 1) A known allergy to minocycline or any tetracycline. 2) No 
molecular confirmation of the AS diagnosis. 3) Participation in another study in which a drug, 
vitamin or dietary manipulation was used to treat AS within 6 months preceding enrollment. 4) 
Severe or uncontrolled seizures or another medical condition(s) rendering the child medically 
unstable. 5) A history of cardiovascular, respiratory, liver, kidney or hematologic disease or a 
history of systemic lupus erythematosus. 
Medical and Neuropsychological Evaluation 
Each participant underwent 3 identical study visits consisting of medical evaluation and 
neuropsychological examination at baseline, after 8 weeks of treatment with minocycline, and 8 
weeks after the drug was discontinued. A board-certified pediatric neurologist completed a detailed 
history and physical examination, assigned a Clinical Global Impressions – Severity (CGI-S) score 
and interpreted the results of laboratory testing. As a safety measure, a complete blood count 
 43 
(CBC), as well as blood urea nitrogen (BUN), creatinine, alanine amino transferase (ALT), and 
aspartate aminotransferase (AST) levels was obtained at each time point to ensure proper function 
of multiple organ systems. A routine 30-minute electroencephalogram completed the medical 
evaluation. Neuropsychological measures were administered during each study visit. These 
outcome measures included the Bayley Scales of Infant and Toddler Development 3rd Edition 
(BSID-III), Vineland Adaptive Behavior Scales, 2nd Edition (Vinland-II), and Preschool 
Language Scale, 4th Edition (PLS-IV). To ensure compliance with the dosing regimen, caregivers 
were asked to record the date and time each dose of minocycline was administered. 
Safety and Adverse Event Monitoring 
Prior to the initiation of any study procedures both parents (or a legally authorized 
representative) of participants were required to sign an informed consent document in person. The 
document detailed all of the study procedures and each of the known side effects of minocycline. 
During the course of the study, caregivers were asked to report any observed side effects and/or 
changes in behavior immediately via telephone. After 4 and 8-weeks of minocycline treatment as 
well as 4 and 8-weeks after the drug was discontinued caregivers were asked to complete online 
questionnaires to document adherence to the medication regimen and to document any observation 
the caregiver may have made. To assess the safety of minocycline on multiple organ systems, the 
aforementioned blood-screening tests were reviewed during each study visit. When an adverse 
event was reported, the duration, severity, relatedness and treatment status were documented 
(Table 3-1). 
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Table 3-1. A Summary of Adverse Events 
Participant Description of symptoms 
Latency to onset 
(Days) 
1 Feminine Yeast Infection 24a 
2 Seizure - Atypical Absence 56a 
3 Commencement of Menstruation 27a 
4 Difficulty Standing & Balancing 63 
5 Dark Spots on Shins 18a 
8 Lethargy/Sleepiness 18a,b 
10 Sleepiness 20a,b 
11 Diagnosis of Lyme Disease 112 
13 Urinary Tract Infection 57 
15 
Seizure - Tonic-Clonic & Difficulty 
Ambulating 
9a 
21 Influenza Type A 57 
22 Sleepiness and Difficulty Ambulating 39a,b 
24 Seizure 110c 
25 Seizure Associated with Fever & Vomiting 113 
a Adverse event occurred during minocycline treatment. 
b Participant required a dose adjustment. 
c Subject withdrew due to adverse event. 
Minocycline Dosing 
After baseline testing, each subject was prescribed minocycline according to his or her 
body weight (3 mg/kg/day, not exceeding 200 mg a day). The drug was dispensed in 50 mg caplets 
to be taken orally twice daily (BID). While the lack of speech made it difficult to discern, 3 
participants taking 200 mg per day appeared to suffer from intolerable lethargy and/or dizziness 
(Table 3-1). The adverse effects resolved when the dose was reduced to 100 mg daily. The dosages 
used here are equivalent to those used in clinical practice for children greater than 8 years of age 
and have been established as tolerable and safe in similar patient populations (Fanning, Gump et 
al. 1977, Goulden, Glass et al. 1996). 
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Statistical Analysis 
For each dependent measure, the effect of minocycline treatment was assessed using 
repeated measures analysis of variance (ANOVA) with P values of less than 0.05 considered 
significant. Post hoc Dunnett’s tests were performed to isolate significant changes from baseline 
assessment values. A 2 x 3 mixed factor ANOVA was performed with age (≤9 or >9 years old) as 
a between groups measure and assessment time as a repeated measure. For all analyses, partial η2 
(effect size) was calculated according to the guidelines of Cohen (0.01 = small effect, 0.06 = 
moderate effect, 0.14 = large effect) (Cohen 2013). 
Primary Outcome Measure 
Bayley Scales of Infant and Toddler Development, 3rd Edition was administered consistent 
to the test manual, under the direct supervision of a board-certified neuropsychologist, and by a 
single pyschometrician who was blind to the purpose and phase of the study. The BSID-III is a 
measure of development used to assess the cognitive, language and motor abilities of children ages 
1 to 42 months. The BSID-III yields scores for five developmental domains: Adaptive Behavior 
(self-care and self-direction), Cognitive (attention, memory, sensorimotor, and visual preference), 
Language (receptive and expressive language functions), Motor (fine and gross motor) and Social-
Emotional (using emotional signals for self-regulation and communication needs). Internal 
reliability of the BSID-III is high, ranging from α = 0.086 to 0.93 in healthy subjects. We chose to 
administer this test because: 1) it has been shown to be reliable and valid with high correlation 
coefficients for test-retest reliability in children with other neuropathologies (Black and Matula 
2000); 2) the BSID-III is a common data element suggested by the National Institutes of Health 
(NINDS) for clinical research involving children with Epilepsy, stroke and other neurologic 
disorders (N.I.H. 2014); and 3) literature suggests the BSID-III is an appropriate neurocognitive 
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measure to use in children, such as those with AS, that exhibit profound developmental delays 
(DeWitt, Schreck et al. 1998, Peters, Goddard-Finegold et al. 2004, Peters, Bird et al. 2010). Under 
normal circumstances raw scores are converted to standard scores based on age-matched healthy 
normative data. Children in this sample exhibited raw scores that were well below age-matched 
peers’ performances, which would result in standard scores at the floor of the distribution. Past 
research using the BSID-II in children with AS reported raw scores (Peters, Goddard-Finegold et 
al. 2004). Moreover, reporting raw scores adheres to the STROBE reporting guidelines (Loring 
and Bowden 2014). Finally, utilizing raw scores may better reflect clinical change in functional 
ability that could be observed for children with profound neurocognitive deficits (e.g., increase in 
the number of spoken words, or initial expression of speech) that remains far below expectations 
for age-matched healthy peers and not reflected in standardized scores. Therefore, this study 
employed raw scores to provide a quantitative assessment of skills and abilities of the BSID-III 
domains in our analyses (Peters, Goddard-Finegold et al. 2004, Education 2008). 
Secondary Outcome Measures 
The secondary outcome measures include the Vineland Adaptive Behavior Scales 2nd 
Edition (VABS-II) and the Preschool Language Scale 4th Edition (PLS-IV). The VABS-II is a 
designated NIH common data element for assessment of adaptive skills across 4 behavioral 
domains: Communication, Daily living skills, Socialization, Motor ability and also assesses 
maladaptive behaviors. Scores are based on subjective ratings of parent’s/primary care provider’s 
perception of a child’s ability to complete various behaviors/tasks. The VABS-II was designed for 
special needs children, including those with intellectual disabilities, autistic spectrum disorders 
and ADHD. The test provides normative data for individuals from birth to age 90 years old. 
Internal reliability for early childhood, birth through 36 months, is α = 0.79 to 0.95 and varied 
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from α = 0.83 to 0.93 for children aged 4 to 5 years old. Inter-rater reliability of two different 
caregivers for the same individual aged birth to 6 years old were moderate to large, ranging from 
α = 0.61 to 0.82. (Peters, Bird et al. 2010, Loring, Lowenstein et al. 2011, Thibert, Pfeifer et al. 
2012). The PLS-IV is well-recognized interactive and comprehensive assessment of 
developmental language for children aged birth to 7 years, 11 months of age. Assessment provides 
scores for Total language ability, Auditory Comprehension and Expressive Communication. 
Internal reliability of measures are generally high, ranging from α = 0.80 to 0.97. Both the 
Vineland-II and the PLS-IV have been used extensively in research evaluating developmental 
language deficits across a variety of developmental disabilities, including Angelman syndrome 
(Bird, Tan et al. 2011). 
Clinical Assessment 
A physical examination and EEG assessment was performed at baseline (T1), after 8 weeks of 
minocycline treatment (T2) and after an 8-week washout period (T3). At every time point, a board-
certified pediatric neurologist utilized the clinical global impressions severity scale to rate the 
severity of the participant’s condition, where 0 represents no symptoms and 7 the most severe 
symptoms. This scale provides a quantitative measure of symptom severity that allows the 
clinician to take into account the participant’s history, symptoms, behavior and how his or her 
disability impacted daily living before and after treatment (Busner and Targum 2007). 
A routine 21-channel EEG study was performed utilizing a standard 10/20 system of 
electrode placement. 30 to 60 minute EEG recordings in the awake and, whenever possible, asleep 
states were obtained without sedation. After the conclusion of the study, each EEG recording was 
de-identified, and placed in random order so that the EEG order and relation to treatment were not 
known. A scoring system was used to evaluate several aspects of the EEG recordings regardless 
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of whether or not they were a part of AS specific EEG patterns. Points were assigned when a 
particular characteristic was observed. For example, 1 point was given if an EEG was abnormal 
overall. Characteristics that would be considered more abnormal were scored accordingly. For 
instance, when evaluating the EEG background, 1 point was assigned if primarily theta waves 
(mild slowing, >50%) were observed. When a mixture of theta and delta waves (moderate slowing) 
were observed, 2 points were assigned. When primarily delta waves (severe slowing, >50%) were 
recorded 3 points were assigned. Other EEG characteristics were also examined including occipital 
rhythm (normal-1, slow-2 and absent-3), rhythmic theta (present <50% of the time-1, present 
>50% of the time-2), rhythmic delta (present-3) and epileptiform abnormalities (present-1, focal-
1, multifocal-1, generalized-1, seizure-2). The points were totaled resulting in a total score, ranging 
from 0 (most normal) to 24 (most abnormal). 
Results 
Study Participants: 11 female and 14 male children, mean age 8.2 years old, were enrolled 
in the study. Of those enrolled, 21 participants were confirmed to have a maternal deletion (the 
number of deleted bases was variable) and 4 were positive for a mutation of the UBE3A gene. 
Twenty-four children completed the 16-week open-label study; one participant withdrew at week 
16 due to unrelated seizure activity. 
Primary Outcome Measure 
A significant improvement in raw scores of the communication subscale of Bayley-III 
(Table 3-2) was observed at T3 when compared to T1, F(2,46) = 3.72, p < 0.05. Post hoc analysis 
revealed scores from participants between the ages of 4 and 9 years old were responsible for a 40% 
increase, while scores from participants between ages 9 and 12 years of age remained unchanged. 
Moreover, a significant improvement, F(2,46) = 5.011, p < 0.05, of the subscale self-direction was 
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observed at both T2 and T3 compared to T1. While no change was observed in gross motor ability, 
a significant increase (15%) in the measure of fine motor ability was observed at T3 when 
compared to T2, F(2,46) = 3.28, p < 0.05. 
Neuropsychological Outcomes 
 A significant improvement in the raw scores of the receptive communication index of the 
Vineland-II was found between T2 and T1, F(2,46) = 6.73, p < 0.05. Two domains of the PLS-IV, 
auditory comprehension and total language ability, were both found to have increased significantly 
when measures at T3 were compared to T1, F(2,44) = 6.73, p <0.05 and F(2,44) = 5.84, p <0.05, 
respectively. 
Table 3-2. Neuropsychological Outcome Measures 
 
Bayley Scales of Infant and Toddler Development, 3rd Edition 
 Cognitive Communication Language Motor Self 
   Receptive Expressive Gross Fine Care Direction 
T1 26.4 ± 2.48 18.9 ± 1.60 13.4 ± 0.61 10.1 ± 0.76 41.3 ± 1.69 19.4 ± 1.05 37.8 ± 1.81 33.8 ± 2.24 
T2 31.7 ± 1.83 22.8 ± 1.69 13.7 ± 0.81 11.8 ± 0.75 40.5 ± 1.60 19.8 ± 1.47 40.6 ± 1.84 *38.1 ± 1.98 
T3 30.7 ± 2.09 *23.5 ± 1.88 13.8 ± 0.68 11.2 ± 0.68 42.8 ± 1.12 †22.4 ± 1.5 40.0 ± 1.99 *39.5 ± 1.94 
η2 0.05 0.05 0.002 0.04 0.02 0.03 0.02 0.06 
 
Vineland Adaptive Behavior Scales, 2nd Edition 
 Maladaptive Behavior Communication Motor Daily Living Skills 
 Internal External Receptive Expressive Gross Fine Personal Domestic 
T1 6.7 ± 0.44 5.5 ± 0.58 30.3 ± 1.62 41.8 ± 3.02 48.3 ± 3.27 99.0 ± 7.12 53.8 ± 5.61 2.6 ± 0.95 
T2 5.5 ± 0.47 4.7 ± 0.57 *36.4 ± 2.42 44.3 ± 3.23 48.9 ± 3.32 101.2 ± 7.5 59.1 ± 5.75 3.8 ± 1.49 
T3 5.7 ± 0.52 6.0 ± 1.25 33.9 ± 2.25 43.8 ± 2.58 49.4 ± 3.25 95.4 ± 7.84 56.4 ± 4.95 2.7 ± 0.92 
η2 0.05 0.02 0.06 0.06 0.001 0.004 0.007 0.01 
 
Preschool Language Scale 
 Auditory Comprehension Total Language Expressive Communication 
T1 17.64 ± 0.68 34.20 ± 1.58 16.3 ± 1.14 
T2 18.25 ± 0.58 34.88 ± 1.36 16.6 ± 0.94 
T3 *20.48 ± 0.71 *38.83 ± 1.34 17.5 ± 0.71 
η2 0.13 0.08 0.001 
Mean ± Standard Error. 
η2 (Partial Eta squared) is a measure of effect size. 0.01 suggests a small effect, 0.06 a medium effect and 0.14 a large effect. 
* p < 0.05 when the time point is compared to T1 (baseline). 
† p < 0.05 when the time point is compared to T2 (after treatment with minocycline). 
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Clinical Outcomes 
Blood screening tests showed no clinically significant changes over the 16-week study 
course and no serious adverse effects related to minocycline treatment were reported (Table 3-1). 
In 3 cases, caregivers reported lethargy and/or dizziness that required a dose adjustment and was 
considered related to the minocycline treatment. All of these participants were receiving 100 mg 
of minocycline BID. In 2 other cases, caregivers reported difficultly standing and/or walking that 
resolved after the discontinuation of minocycline. A significant clinical improvement over T1, for 
all participants, as measured by the CGI-S score (Table 3-3), was observed at T2 and T3 [F(2, 46) 
=13.20, p < 0.05]. Analysis of EEG scores revealed a 4.3% and 10.8% improvement when T2 and 
T3 observations were compared to baseline but did not reach the level of significance [F(2,46) = 
1.494, p > 0.05]. For both measures, calculated partial η2 was equal to 0.05, an indication of a 
moderate effect size. 
 
Table 3-3. Patient Populations & Clinical Measures 
   
CGI EEG 
T1 T2 T3 T1 T2 T3 
Mean ±  
Standard Deviation 
5.56 ±1.12 *4.96 ±1.10 *5.08 ±1.25 9.16 ±3.47  8.76 ±2.80  8.16 ±3.47 
Standard Error of the Mean 0.224 0.220 0.255 0.694 0.561 0.709 
η2  0.050   0.050  
η2 (Partial Eta squared) is a measure of effect size. 0.01 suggests a small effect, 0.06 a medium 
effect and 0.14 a large effect. 
* Indicates p < 0.05 when the time point is compared to T1 (baseline). 
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Discussion 
To our knowledge, this is the first prospective trial of minocycline treatment in which 
safety, tolerability, cognitive function and adaptive behavior were evaluated among children with 
Angelman syndrome. Statistically significant changes were observed across several subscales with 
moderate relative effect sizes (Table 3-2) in both the primary and secondary outcome measures 
when language ability and self-direction at T2 and T3 was compared to T1 and communication 
skills at T3 was compared to T1. When the mean scores for all participants were analyzed, a 
significant improvement in communication and fine motor ability was observed. Participants also 
showed a significant improvement in self-direction, the ability to entertain themselves and follow 
simple directions, after being treated with minocycline. This suggests minocycline may have 
positive effects on aspects of the central nervous system resulting in improvements in language, 
fine motor skills and some adaptive behaviors. While raw scores had to be used considering the 
cognitive and language deficits of these children, the improvements in cognition, language and 
motor skills were perceived by caregivers as shown by the VABS-II results. These pilot data show 
minocycline may improve the pervasive cognitive and language deficits of these patients over a 
16-week period. 
The effects of minocycline were also observed clinically as shown by clinician rated 
function (CGI-S) scores. No significant change in the EEG scores was observed. However, this 
was measured with consistent anti-seizure medication and concurrent treatment of minocycline. 
Thus, it is unclear whether minocycline has an effect on EEG patterns of AS patients not receiving 
treatment for seizure. Caregivers reported few adverse effects and no severe adverse events related 
to minocycline treatment. Language limitations required adverse event reports from caregivers 
rather than participants themselves. In 3 cases, lethargy and/or dizziness was reported in 
participants taking 200 mg of minocycline daily. These symptoms subsided after the dosage was 
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reduced, suggesting a smaller dosage may be required to mitigate adverse effects. We show 
statistically significant results after MC treatment was discontinued (T3) suggesting a lasting 
treatment effect or persistent placebo effect. The optimal treatment course may be more extensive. 
Therefore, further study is needed to determine the optimal length of treatment and what effect 
extended exposure to minocycline may have in the AS patient population. In general, these data 
suggest the short-term use of minocycline at these dosages in children with AS is well tolerated. 
Several notable limitations of this pilot study include the behavioral manifestations of the 
participants, single arm study design, lack of control for practice effect, and small sample size. As 
expected, the behavioral characteristics of the participants (low tolerance for frustration, limited 
language skills, articulation patterns that made speech intelligible only to caregivers) interfered 
with their performance on the neuropsychological instruments. However, these behavioral deficits 
reflect the severe cognitive and language impairments of these individuals and account for their 
below age level skills in self-care and social behaviors. Moreover, the preponderance of the testing 
consists of questionnaires and relies on parent responses that may include bias. Regardless, we 
chose to employ the same neuropsychological instruments used in previous studies of AS patients. 
This includes the Bayley Scale of Infant and Toddler Development – 3rd Edition despite the age 
limit of 42 months. 
Future research to explore therapeutic benefits of minocycline in AS should involve studies 
with a placebo-controlled crossover design to better control for practice and temporal effects. The 
study design also did not allow for evaluation of practice effects particularly from T1 to T2. 
Previous research is replete with data indicating practice effects are present in neuropsychological 
assessments and are often most pronounced between first and second testing periods and decrease 
from second to third testing periods. It is important to point out that there are no published results 
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studying practice effect in children with Angelman syndrome. Moreover, the calculated η2, the 
results reported here show the associated improvement in neuropsychological measures reflected 
an actual treatment effect not attributable to practice or error. 
Conclusion 
The data reported here show the administration of minocycline to children with Angelman 
syndrome is safe and well tolerated. Moreover, we show minocycline improved the adaptive 
behavior of these children suggesting this drug may be an effective treatment of this disorder. It is 
important to determine the optimal treatment dosage as well as the effects of long-term use in this 
patient population. Therefore, future controlled studies are recommended before minocycline is 
used generally as a treatment for Angelman syndrome. 
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CHAPTER 4 
 
NEUROPSYCHOLOGICAL TESTING REVEALS THE NEED FOR A NOVEL 
OUTCOME MEASURE IN THE ANGELMAN SYNDROME POPULATION 
Background 
Several genetic aberrations involving the UBE3A gene result in the expression of the AS 
phenotype. In most tissues both the paternal and maternal alleles (chromosome 15q11.2) coding 
for this protein are expressed equally (Jiang, Lev-Lehman et al. 1999). In contrast, neurons only 
express the maternal allele; therefore, any mutation or deletion results in a non-functional gene 
product (Albrecht, Sutcliffe et al. 1997). Normal expression of UBE3A results in the production of 
ubiquitin protein ligase E3 (Ube3A), an enzyme that localizes to pre-synaptic and post-synaptic 
compartments of neurons and is required for normal synaptic function (Gustin, Bichell et al. 2010). 
Thus, there is an ongoing initiative by our lab and others to develop or identify a therapeutic with 
the potential to restore synaptic function, which, in turn, may ameliorate the motor and cognitive 
deficiencies experienced by individuals with AS. One major challenge in assessing the symptoms 
in any single individual with AS is the wide etiologic variation and wide-ranging severity of known 
symptoms.  
There is an urgent need to identify outcome measures that are adequately sensitive, 
specific, reliable and valid to demonstrate treatment benefit for pharmacologic interventions or 
behavioral trials developed for use in Angelman syndrome, particularly in children. Our 
experience revealed the severe developmental delay, cognitive impairment and deficits in speech 
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prevent the child with AS from performing on the current neuropsychological tests. The cognitive 
and behavioral assessments most typically used is the Bayley Scales of Infant and Toddler 
Development-3rd Ed. (BSID-III; Bayley, 2005) and/or Vineland Adaptive Behavior Scales-2nd Ed. 
(VABS; Sparrow et al., 2005). Due to the behavioral characteristics of the syndrome, all children 
with AS exhibit raw scores at the bottom of the testing scale. This results in a lack of variance 
between children (a floor effect) in which no difference between individuals can be seen (Figure 
4-1) and, in the case of experimental therapeutics, small changes will not be detected.  
 
Expressive & Receptive Communication Scores 
Participant Bayley III- ECC Bayley III - RCC 
 Raw Standard Raw Standard 
1 15 1 13 2 
2 12 1 15 3 
3 12 1 15 3 
4 7 1 9 1 
5 18 2 30 7 
6 17 1 15 3 
 
Figure 4-1. Current Standardized Measures are Insensitive to the Cognitive and 
Behavioral Abilities of Children with Angelman Syndrome.  
A) Participant raw and scaled scores in the expressive (ECC) (16.2±2.9 & 3.2±1.0) and 
receptive (RCC) (13.5±1.6 & 1.2±0.2) communication domains of the Bayley Scales of Infant 
and Toddler Development. B) Participant raw and scaled scores in the expressive (40.7±4.8 & 
1±0) and receptive (32.7±4.7 & 4.8±2.1) communication domains of the Vineland Adaptive 
Behavior Scales. 
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Our research has revealed the quantification of behavioral characteristics of Angelman 
syndrome from recorded observations is possible and is reliable between raters. Moreover, we 
show that children with AS use more primitive forms of communication which is likely related to 
a childhood apraxia of speech compounded by deficits in receptive and expressive language. 
Finally, children with Angelman syndrome exhibit not only a wide based gait, but other abnormal 
parameters of gait that can be combined into an index and used as a potential biomarker when 
therapeutics are applied. This research identifies, for the first time, a measure that quantifies an 
individual’s overall level of severity of Angelman syndrome within the population and would in 
turn facilitate assessment of natural development, behavioral modification, and therapeutic 
intervention.  
Methods 
To date only 4 clinical research studies have been attempted in the Angelman syndrome 
patient population. First, recruitment is still underway for an observational, longitudinal study 
named the Natural History Study aimed a better understanding the natural progression of the 
patient with AS throughout the lifespan. The second is a completed study in which folic acid 
supplementation would increase expression of the paternal UBE3A allele by altering DNA 
methylation (Peters, Bird et al. 2010). The researcher hypothesized the effect of folic acid 
supplementation would be enhanced by the addition of betaine (Dan, Servais et al. 2004).The third, 
is the ongoing clinical trial using levodopa which aims to increase fine motor ability by decreasing 
the amount of tremor that is associated with the syndrome. Finally, our recently concluded clinical 
trial using the antibiotic minocycline showed small but significant changes in communication and 
self-care (Grieco, Ciarlone et al. 2014). In each of these four studies, outcome measures relied 
upon neuropsychological tests including the Bayley Scales of Infant and Toddler Development 
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(Bayley-III), Preschool Language Scale, 4th Edition (PLS-4), Aberrant Behavior Checklist (ABC) 
and the Vineland Adaptive Behavior Scales (VABS) in order to make historical comparisons 
between the results, and due to the lack of available alternatives.  
Study Design 
Currently, the clinical features of AS included in chapter 1 (Table 1-1) are used to diagnose 
the disorder, which is then confirmed by a cytogenetic workup (Buntinx, Hennekam et al. 1995, 
Williams, Beaudet et al. 2006). We are limited by an absence of a documented global scale for 
these features in Angelman syndrome or even specific scales of dynamic range for each individual 
feature. We identified several behavioral domains; communication, attention, maladaptive 
behaviors, and hyper-excitability that are most disturbed in patients with Angelman syndrome.  
Participants 
 Participants with Angelman syndrome were recruited through an Angelman syndrome 
support group. A convenience sample of typically developing children were recruited from siblings 
of the participants with AS and from the community. This study was reviewed and approved by 
the University of South Florida’s, Human Research Protection Program’s Institutional Review 
Board (Protocol Number Pro00004716). Signed informed consent was obtained by at least one 
legally authorized representative prior to participation in this study. Moreover, assent was obtained 
from each unaffected child 7 years of age or older. Inclusion and exclusion criteria required that 
participants with AS have a molecular confirmation of their diagnosis and that they have not 
received any therapeutic to treat the symptoms of AS within the preceding 12 months.  
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Communication 
To quantify the communication behavior, participants were placed in a room with a 
licensed speech and language pathologist and engaged in an unstructured play session to elicit 
speech and non-verbal communication attempts. Four cameras mounted in various positions 
captured video recordings with audio. In addition, audio was recorded and analyzed using the 
LENA Pro™ analysis system which segmented the audio recordings into vocalizations surrounded 
by 300ms of silence. Speech attempts by the child were transcribed phonetically and categorized 
into five different types of vocalizations using the Stark Assessment of Early Vocal Development-
Revised (SAEVD-R) (Nathani, Ertmer et al. 2006) which categorizes non-speech and pre-speech 
sounds (protophones), as well as vowels, consonants and syllables. This 5 point scale differentiates 
segments based on resonance, duration and speed of transition between sounds. Consonant-vowel 
(CV) utterances were analyzed further into frequently occurring (labial/central, coronal/front, 
velar/back) and less frequently occurring CV combinations (Giulivi, Whalen et al. 2011) and a 
phonetic inventory was developed.  
Video recordings of the session were analyzed for gesture use using Noldus Observer® 
software. Gestures were classified (Table 4-1) as deictic (which establish reference by calling 
attention to or indicating an object) or representational (which establish reference and indicate 
specific semantic content) and the function of the gesture was established as: 1) Behavior 
regulation -- requesting objects, protesting; 2) Social interaction -- including greetings, joint 
attention (showing, commenting) and shared engagement (Crais, Watson et al. 2009). Children 
who utilize more representational gestures and engage in more joint attention are more likely to 
communicate verbally or use an augmentative communication device. 
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Table 4-1. Gesture Function Subtypes  
Gesture Function Subtype Descriptive Example 
Behavioral Regulation 
Deictic Child reached for an object 
Representational 
Child pretended to drink from a cup when 
holding an empty cup 
Social Interaction 
Joint Attention 
Child focused on the same object as the 
clinician 
Shared Engagement 
Child engaged in activity with the 
clinician 
Adaptive Behaviors 
 Adaptive behaviors of children with Angelman syndrome and healthy control children 
were coded using the Noldus Observer® XT software as described in the communication section 
above. Patients with AS have been described as hyper-active, that is, they spend little time in a 
stationary position. As such, they tend not to focus on one particular task for any appreciable length 
of time. While not an indication of their emotional state, persons with AS also exhibit a persistent 
happy demeanor and show hyper-excitability by way of hand flapping and laughter, often at 
inappropriate times. As with the assessment of communication, 3 independent reviewers, 
quantified the frequency and duration of the behaviors; attention span, laughter and mobility from 
video recordings. Later, these data were analyzed using descriptive statistical methods and Intra-
rater and Inter-rater reliability for each behavior was calculated.  
Statistical Analysis 
An omnibus analysis of the measurements collected using the Angelman syndrome 
assessment instrument was analyzed by multivariate analysis of variance (MANOVA) to 
determine the degree of association between each component of the scale and whether each 
component of the measurement scale can effectively differentiate symptom severity among healthy 
control and children with Angelman syndrome. Following omnibus analysis, Bonferroni planned 
comparisons was utilized to isolate effects duration of non-specific noises, attention span, 
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ambulation and laughter. The intra-class correlation (ICC) is a commonly used statistic to describe 
the magnitude of disagreement between two or more raters (inter-rater reliability) or between a 
single rater at two or more different time points (intra-rater reliability). To determine intra and 
inter-rater reliability, results from 3 randomly selected participants, were coded by 4 independent 
raters and recoded by the original rater. Absolute agreement was determined by calculating an ICC 
coefficient using a two-way random model utilizing SPSS (IBM Corp. Released 2013. IBM SPSS 
Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp). A coefficient value of ≥0.7 was 
considered an acceptable level of reliability with value of ≥0.8 representing an ideal amount of 
reliability (Hallgren 2012).  
Gait Assessment 
 Gait abnormalities occur in every known case of AS. While some patients with AS may 
not walk at all, neurologic examination reveals an unsteady, wide based gait (Figure 4-2), in 
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Figure 4-2. Children with Angelman Syndrome Exhibit Gait Anomalies Including Such as 
Wide Based Gait.  
A) Stride width measurements of 6 children with Angelman Syndrome age 4 to 11, 𝑥 = 15.1 
(left) and 𝑥 = 15.0 (right) (n=6) compared to healthy control children, 𝑥 = 9.7 (left) and 𝑥 = 9.63 
(right), of the same age (n=5) reveal participants with AS require a larger base of support during 
walking. The dotted rectangle indicates the average range, 𝑥 = 8.5 to 13.7, for typically 
developing children ages 4 to 11. B) Analysis software calculates the stride width by measuring 
the distance between the heel strike of one foot and the heel strike of the contralateral foot as 
shown in (B). This results in two measure of stride width, left and right.  
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conjunction with rigid, ataxic movements of the legs. Previous research has shown patients with 
ataxia present with a widened base, unsteadiness, and irregularity of steps with veering to one side. 
Further, analysis of temporo-spatial gait parameters in patients with ataxia (without AS), reveal 
lower cadence and step length while gait velocity, step width, stance phase and outward rotation 
is increased when ataxic gait measures are compared to age matched norms (Oberg, Karsznia et 
al. 1993, Dusing and Thorpe 2007, Fiorillo, Rinaldi et al. 2010). As with language development, 
current tests evaluating development provide limited assessment of walking or any ambulatory 
method. During our evaluation, children with AS walked down an instrumented walkway (Zeno 
Walkway, ProtoKinetics, Havertown, PA; manufactured by Zenometrics, Peekskill, NY) at a self-
selected pace for 4 to 6 trials and gait parameters were determined using ProtoKinetics Movement 
Analysis Software (PKMAS; ProtoKinetics, Havertown, PA). Due to behaviors inherent to the 
syndrome, such as attention span and the inability to follow directions, not all data collected could 
be used. As such, a minimum of 8 footfalls (left and right pairs) were used in the analysis. Partially 
captured footfalls and footfalls not video recorded were excluded from the analysis. Five primary 
spatiotemporal parameters were analyzed: cadence, gait velocity, stride width, step length and 
percent stance. For each parameter, group means were used to complete a principal component 
analysis (PCA) and a gait index was created for the data. This was completed using the mean and 
standard deviation calculations from the typically developing (control) participants and calculating 
z-scores for all the data points. To generate the participant’s performance on each component, the 
z-scores were multiplied by the associated loading values for that component and summed. The 
results represent a particular participant’s deviation from prototypical performance for that 
component. Finally, the absolute values of each component score are summed to yield the 
participant’s gait index. This number represents the overall deviation from prototypical gait (the  
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average gait of controls). Stated plainly, as the gait index score increases (moves away from 0), 
the more deviant the gait of the AS participant is from the average gait of the typically developing 
participants.  
Results 
Communication 
 Speech attempts by 9 children with AS were transcribed and categorized into five different 
types of vocalizations using the Stark Assessment of Early Vocal Development-Revised. Results of 
our study (Figure 4-3) showed none of the children with AS used advance forms of vocalizations 
(Diphthongs, Jargon, or Complex syllables). However, the mean frequency of reflexive (cry & 
discomfort, vegetative sounds) vocalization was observed 11.25 times, control of phonation (single 
consonant or consonant-vowel, chuckle/laughter) 25.5 times and expansion (single vowels, vowel 
glides, squeals, marginal babbling) 17.88 times. Few canonical syllables (single consonant-vowel, 
syllable strings, whispered vocalizations, or disyllables) were observed in the participants with AS 
(5.67 times). In contrast, a cognitively matched, typically developing participant (n=1) used more 
advanced levels of vocalizations including expansion (8 times), canonical syllables (50 times) and 
advanced forms of vocalization (3 times).  
While most of the vocalizations we observed were either laughter or isolated vowels, three of the 
children with AS produced consonant-vowel (CV) combinations. These limited productions were 
characterized as either labial/central or velar/back CV combinations (Giulivi, Whalen et al. 2011). 
The phonetic inventories of the entire group of children with AS was limited to the following 
consonants: /,m,n,j,w,h,b,d,g,k/. All children with AS produced the /j,w,h/ and either /m/ or /n/. 
Approximately one-half of the children produced the plosives /b,d/ and only one child produced 
/k,g/. In terms of vowels, the children with AS tended to use central and low vowels and a few 
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children produced high vowels. These consonant patterns taken together with a preference for 
either front or back vowel usage suggests little tongue movement during speech production, which 
may be related to the presence of childhood apraxia of speech. It was also noted that the children 
with AS kept their tongue in a central position within their mouth the majority of the time.  
Considering the speech production findings mentioned above, we investigated the use of 
gestures as a form of communication in this Angelman population. Using the Noldus Observer® 
XT software, gesture function (Table 4-2) was coded as behavioral regulation or social interaction 
and further classified as deictic or representational (with in the behavioral regulation category) and 
joint attention or shared engagement (with in the social interaction category).  
 
 
 
Figure 4-3. Children with AS Use Less Developed Forms of Communication. 
Using an observational method of testing, the frequency of vocalization for patients with 
Angelman syndrome was measured. Vocalizations were then categorized using the Stark 
Assessment of Early Vocal Development - Revised. Results revealed participants with AS most 
commonly used single consonant, consonant-vowel or laughter forms of communication (control 
of phonation) suggesting these children possess the vocal ability of a very young child (< 2 years 
of age). 
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Table 4-2. Characterization of Gesture Use in Children with Angelman Syndrome 
Gesture 
Function 
Subcategory 
# of 
participants 
(AS) in which 
the behavior 
was observed 
Average 
Percentage of 
Time Spent 
Mean Number of 
Gestures Used 
AS 
TYPICAL 
N=1 
AS 
TYPICAL 
N=1 
No Gestures   - 50.0% 29.43% - - 
Behavioral 
Regulation  
Deictic  9 16.55% 18.12% 28.92 18.12 
Representational 1 0.27% 0% 3.87 0 
Social 
Interactive  
Joint Attention 9 15.71% 37.05% 19.89 19.71 
Shared Engagement  5 
The short attention span of children with 
AS made it difficult to discern between 
joint attention and shared engagement. 
 
These data show: 1) Children with AS used relatively equal amounts of the earlier 
occurring gesture types (deictic gestures and joint attention). 2) Children with AS spent nearly 
twice as much time not gesturing when compared to typically developing, younger children. 3) 
Typically developing children spent more time in joint attention and used fewer deictic gestures 
to communicate than the children with AS. 4) Representational gesture use was only observed in 
1 child with AS. 5) Overall, the children with AS performed differently than the typically 
developing children, emphasizing be havioral regulation more than social interaction in the 
communicative attempts.  
Adaptive Behavior: 
Using the Noldus Observer® XT software, 30 minute video recordings (with audio) were coded 
and behaviors characteristic to Angelman syndrome were quantified (Williams 2010). Results of 
an Omnibus MANOVA test revealed a significant difference [F(5,10) = 19.602, p < 0.05] between 
participants with AS (n=7) and the typically developing children (n=9) existed. As expected, we 
observed large differences in the attention span (mean % of time = 5.0) and a significant difference 
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[F(1,14) = 124.5, p < 0.05] in inappropriate laughter (mean % of time = 23.2) of participants with 
AS when compared to typically developing children who showed an increase the length of 
attention (mean % of time = 19.6) and a decrease in inappropriate laughing (mean % of time = 0.7) 
respectively (Figure 4-4). Interestingly, children with AS spent a similar amount of time making 
non-specific noises (sound emitted from the mouth but not vocalizations) compared to typically 
developing children. However, when we coded non-specific noises in conjunction with intention 
(attempts to respond or gain interaction with the examiner), results of children with AS (mean % 
of time = 1.8) were twice that of the control group (mean % of time = 0.9).  
Gait Assessment 
 Measure of spatiotemporal gait parameters (Table 4-3) revealed children with Angelman 
syndrome exhibit decreased cadence and step length but an increase in stride width, % stance, gait 
velocity and Base width which has recapitulated the results of Fiorillo et al. in patients with ataxia 
without cognitive impairment (Fiorillo, Rinaldi et al. 2010, Prosser, Lauer et al. 2010). In contrast, 
 
 
Figure 4-4. Analysis of Behavioral Coding Reveals Stark Differences Between Individuals 
with AS and Typically Developing Participants.  
These results coincide with the previously reported characteristic behaviors of Angelman 
syndrome. More variation exists between children with AS than the control group suggesting a 
large sample size is required in order to develop a scale for standardized comparisons. 
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these results reveal a stark contrast between children with AS and typically developing children as 
well those with cerebral palsy and other mental disorders (Wondra, Pitetti et al. 2007, Prosser, 
Lauer et al. 2010).  
 
 A principal component analysis revealed 2 components of gait: 1) The gait velocity is 
determined by the step length and that these two factors are inversely related to stride width. In 
other words, as the stride width increases, as in the case of AS (ataxia), gait velocity decreases. 2) 
An inverse relationship exists between cadence and percent stance. Specifically, as the percent of 
time in contact with the ground increases the cadence decreases. This is intuitive since the cadence 
equals the number of steps per time (min). Subsequent calculation of index scores revealed a mean 
Gait Index of 3.16 ± 0.48 for typically developing participants and a Gait index of 4.94 ± 0.65 for 
participants with AS. An independent t- test with Welch’s correction for unequal group variances 
Table 4-3. Spatiotemporal Parameters of Gait for Children with Angelman Syndrome 
Compared to Previously Reported Models of Ataxia and Norms from 
Typically Developing Children 
 n = 10 n = 10 n = 19 n = 13 
 
Norms 
(3 to 9 
yrs) 
Fiorillo et 
al. (2010) 
ATX 
Prosser et 
al. (2010)   
CP 
Prosser et 
al. (2010) 
TD 
Wondra et 
al. (2010) 
MD 
GASA 
Cadence 
(steps/min) 
138.14 - 
120.23 
116 103.3 155.2 107.6 110.5 
Step Length (m) 0.5 0.45 0.55 0.76 0.75 0.44 
Stride Width (m) 0.05 0.1 - - - 0.15 
% Stance Phase 40 59.3 77.5 84.8 80 60.1 
Gait Velocity 
(m/s) 
0.89 - 1.10 0.87 0.22 - 0.64 0.81 
Base Width (cm) 8.5 – 13.7 - - - 13.4 15.6 
ATX: Ataxia Only   CP: Cerebral Palsy   TD: Typically Developing   MD: Various Mental 
Disabilities   GASA: Global Angelman Syndrome Assessment  
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indicated a significant difference between the two groups, t(22) = 2.201, p < 0.05, with Angelman 
patients exhibiting impaired gait relative to controls. 
Reliability Testing 
Communication 
Two speech samples (18%) were randomly selected and re-transcribed by the original transcriber. 
Intra-rater agreement was 99%. The agreement of gesture coding was accomplished by recoding 
20% of sessions. The original rater recoded 20 minute sections (minutes 5-25) from three randomly 
selected participants for intra-rater agreement. Intra-rater agreement was 97%. One of the original 
speech-language pathologists recoded three different, randomly selected participants for inter-rater 
agreement. Inter-rater agreement was 78%. This value was deemed adequate since children with 
AS do not use social communication in the same way as typical developing children. At times, it 
was difficult to determine the child's intent. For instance, it was difficult to determine if play 
stopped because the child lost interest or if they were indicating that they no longer wanted to play. 
Miles and Huberman report an average agreement percentage of approximately 70% is adequate 
for the preliminary use of a qualitative approach in a novel way (Miles and Huberman 1994).  
Adaptive Behavior 
 Poor ICC coefficients (ICC < 0.7) were revealed when coding results from each of the 4 
raters for 3 randomly selected participants were compared suggesting a larger than desired 
variability between raters (Table 4-4). For instance, ICC coefficients were lower when multiple 
raters coded more subjective behaviors such as noises with intention, inappropriate laughter and 
attention span. However, for behaviors that are more easily defined, such as ambulation (any form 
including but not limited to: walking, crawling or scooting), coding between raters was shown to 
be reliable (ICC = 0.716). In contrast, an ICC greater than 0.8 was observed for each of the rated 
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behaviors when coding results from the same rater at two different time points was compared, 
which is evidence for the repeatability of these measurements utilizing the same rater. 
Table 4-4. Statistical Analysis of Reliability Using the Intra-class Correlation 
Coefficient 
 
Inter-rater Reliability Intra-rater Reliability 
ICC 95% CI ICC 95% CI 
Noises w/ intent 0.554 -0.495 0.987 0.831 -0.34 10.995 
Inappropriate Laughter 0.448 -3.733 0.987 - - - 
Attention Span 0.427 -1.293 0.896 0.836 0.089 0.976 
Ambulation 0.716 -6.717 1.000 0.837 -13.2 0.996 
Two-way random effect model where both rater and measure effects are random. Calculations 
of ICC are using an absolute agreement definition. For inter and intra-rater reliability, an 
instrument should be considered reliable when the intra-lass correlation coefficient ≥0.7, 
however, ≥0.8 is ideal. No laughter was observed in the randomly selected participants, 
therefore ICC for inappropriate laughter could not be calculated. 
Discussion 
 Previous clinical research has shown the development of a novel outcome measure for 
patients with Angelman syndrome is a necessity (Grieco, Ciarlone et al. 2014) to detect change 
when a therapeutic is administered. The behavioral traits inherent to the syndrome, coupled with 
severe cognitive impairment, interfere with the child’s ability to perform the tasks required to score 
above the floor of the instrument. This is not to say they cannot complete the tasks, rather, most 
children with AS are capable of performing the more complex tasks of the Bayley Scales of Infant 
and Toddler Development, but will not complete the task as commanded or in the allotted time. 
As the pipeline for potential therapeutics to treat AS is developed, a measure that can detect a 
change in behavior and ability in this complex population will be required. 
Of the control group, only two participants were younger than the participants with AS. 
However, they demonstrated more advanced communication skills than the children with AS. 
Analysis of the results suggests they desired the socialization aspect of communication more than 
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those with AS, who used primitive communication types to meet their needs. For instance, some 
of the children with AS would touch, hit or attempt to bite the clinician, showing a desire to interact 
and their lack of understanding of how to communicate appropriately.  
As expected, the typically developing children seemed to prefer to use words more than 
gestures to communicate while very few verbalizations, other than laughter, were elicited from the 
children with AS. The participants with AS demonstrated a higher level of receptive language skill 
than evidenced in their expression. For instance, they occasionally responded to clinician requests 
and they would stop an inappropriate behavior when asked. Few consonant and vowel patterns 
were observed, suggest the presence of childhood apraxia of speech. We also noted that the tongue 
of the participants with AS moves very little during speech production, remaining in a central 
position within the mouth. 
Using behavioral coding software, we were able to capture and quantify the behavioral 
characteristics of a child with Angelman syndrome. Moreover, when a specific behavioral domain, 
such as communication, was compared amongst new and existing instruments, it was clear the use 
of an observational method gives rise to more sensitive results demarcating a wide variation in 
ability among children with Angelman syndrome. This increase in measureable variation between 
individuals allows us to use parametric analysis for determining an individual’s disorder severity 
compared to other children with Angelman syndrome as well as highlight particularly small 
changes in behaviors, either regression or improvement, when therapeutics are applied. While 
intra-rater reliability was shown to be ideal, the low ICC values for inter-rater reliability indicate 
large differences in the coding of each rater. These results suggest: 1) Clear definitions of each 
category of behavior and any sub category are needed prior to experimentation. 2) A considerable 
amount of training should be received and an ICC calculated for a particular rater prior to coding 
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behavior during an ongoing study. This training should include several mock coding sessions in 
order for the rater to become familiar with behavioral definitions and software functions. This is 
not uncommon as several standardized exams require certification of the examiner. 3) Whenever 
possible, the same rater should code both baseline and any post treatment recordings. 4) A standard 
set of interactions with the participant during behavioral observation may be necessary in order to 
elicit similar responses between participants.  
While the assessment of behavior and communication is important, quality of ambulation 
is paramount to the quality of life for patients with Angelman syndrome. Until recently, gait 
analysis was a tedious task involving the mapping of a patient’s steps and subsequent calculation 
of numerous gait parameters. Here, using an electronic walkway and PKMAS analysis software, 
we have shown mean gait measurements for 5 parameters of gait said to have the most contribution 
to an ataxic gait. Consistent with the results of Fiorillo et al., results from participants with AS 
were most closely related to patients with ataxia but without cognitive impairment. Similar to an 
apraxia of speech, these results suggest the disability observed in the AS patient population may 
be due to an inability of the brain to communicate properly with the extremities. Further, our ability 
to capture and quantify these spatiotemporal parameters of gait suggests these measures could be 
used as a biomarker when an applied therapeutic is suspected to alter gait.  
Conclusion 
 Angelman syndrome researchers agree, the neuropsychological outcome measures that 
exist currently do not accurately measure the cognition, communication, or motor ability of a child 
with Angelman syndrome. Due to the instrument’s inability to capture changes when a therapeutic 
is applied, researchers risk reporting false negative results even if a positive effect exists. The 
results of this study show that not only can we capture, quantify and analyze the adaptive behavior 
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and motor ability of patients with Angelman syndrome; we can do it with specificity. This means 
the Global Angelman Syndrome Assessment will detect even the smallest amount of change during 
clinical studies of new therapeutics for this devastating disorder.  
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CHAPTER 5 
 
DISCUSSION 
Summary 
 Angelman syndrome (AS) is a congenital disorder caused by an aberration of the maternal 
15q11-13 locus of chromosome 15. These include: deletion (65% of cases), mutation (10%), 
paternal uniparental disomy (5%), and defect of the imprinting center (5%). Still, another 15% of 
patients present with the clinical features of AS, but no molecular abnormality can be detected. 
Therefore, diagnosis of AS is dependent on the presence of certain characteristic features of the 
syndrome including: difficulty feeding as neonates and infants, truncal hypotonacity (6-12 months) 
with rigid, jerky movement of the extremities. Disorders in balance and movement continue 
throughout the patients lifespan and result in characteristic “marionette style” gait. Approximately 
80% of children with AS also suffer from seizures and display a characteristic 
electroencephalogram pattern which is useful in the diagnosis of the syndrome especially when 
molecular testing results are negative.  
Abnormalities in the density and morphology dendritic spines have been shown in the AS 
mouse as well as 1 human female with AS. Moreover, AS mice exhibit severe LTP deficits and 
impaired associative learning. However, studies by our lab, and others, show recovery of the major 
AS phenotypes is possible in the adult AS mouse. These results indicate AS arises from 
biochemical alterations rather that developmental abnormalities. Furthermore, the severity of the 
AS phenotype is likely due to a disorder in global synaptic function.  
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 The mechanism by which the lack of one particular protein, UBE3A, can result in such 
severe global dysfunction is still unknown. To date UBE3A has not been shown to be associated 
with any memory associated protein target. However, the lack or mutation of UBE3A leads to 
alterations in the amount and/or activity of proteins known to play a role in learning and memory 
(i.e. CaMKII, Erk and potassium ATPase) in the AS mouse. For example, when an additional 
mutation in the inhibitory phosphorylation site of CaMKII was introduced in the AS mouse, a 
recovery of the behavioral deficits normally associated with these mice was observed. 
The aforementioned results suggest a reduction in global synaptic function underlies the 
learning and memory phenotype of AS. A therapeutic with the potential to normalize the aberrant 
synaptic function may result in a recovery of these defects. We show AS mice treated with both 
high and low dosages of minocycline exhibited an increase in dendritic spine density and LTP 
when compared to saline treated AS control mice. Moreover, density of spines was increased to 
the level of wild type animals. AS animals receiving the lower dosage also showed an increase in 
associative learning behavior. This suggests that while minocycline alters the structure of dendritic 
spines and the function of synapses, higher dosages can have a detrimental effect on behaviors 
such as learning and memory. It is important to point out, that while we are measuring changes 
using the hippocampus as a model, the effects minocycline has on structure and function of spines 
and synapses are global and not limited to any one brain region and that this global effect is needed 
in order to achieve changes in behavioral output.  
Conclusion 
The field of AS research has rapidly expanded, especially over the last few years, with the 
identification of several potential therapeutics. Differing strategies have focused on replacing the 
missing protein (through the insertion of a viral vector) or increasing paternal expression by 
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“unlocking” the paternal gene (i.e. topoisomerase inhibitors and antisense oligonucleotides). 
While conceptually these therapies possess the potential to increase UBE3A protein in the AS 
brain, the side effects, potential toxicity, invasiveness of the administration and the unclear 
mechanism of the imprinting is likely to significantly increase the time to translation for AS 
patients.  
The main focus of my work is to quickly translate potential therapeutics from the laboratory 
to the human by investigating small molecule compounds, approved by the FDA for use in humans, 
that possess the potential to improve learning and memory in the AS mouse model.  
I have shown one such compound, minocycline, has the ability to normalize dendritic spine 
density, increase LTP and improve hippocampal-dependent memory and in the AS mouse. In a 
human study, I have shown short-term (8 week) use of minocycline is safe and well tolerated in 
children with Angelman syndrome. While we did not observe changes in EEG recordings, 
significant improvement in the clinical global impressions severity scores suggest an improvement 
in symptoms was observed by a child neurologist. Small but significant improvement in the 
adaptive behaviors, communication and self-care were also observed.  
Unfortunately, the available neuropsychological measures were not designed for a patient 
population with severe disabilities. The lack of performance ability resulted in an inability to 
accurately portray the ability of these patients with AS. For this reason, I began to develop a novel 
outcome measure that relies on the behavioral observation rather than the verbal ability of children 
with AS. Using behavior coding software, I find that specific behaviors of these patients can be 
quantified with a high level of intra-rater reliability. Analysis of communication behavior shows 
the presence a childhood apraxia rather than an inability to learn or understand. Moreover the 
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analysis of gait parameters revealed similar results to patients with ataxia without cognitive 
impairment.  
The culmination of my work has provided evidence that a treatment for Angelman 
syndrome is probable. I have shown minocycline has potential to improve synaptic function and 
learning and memory in AS mice and alter certain behaviors in humans. Elucidation by which 
minocycline can recover cognitive impairment in the AS mouse model may shed light on novel 
therapeutic targets for future AS research. Finally, the development of a novel outcome measure, 
specific to Angelman syndrome will provide an accurate assessment of changes in behavior when 
a therapeutic is applied.
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